



MDPV

Nathan J Isotalo to: may.siu

2011-03-30 04:13 PM

Hi May Siu

fya- Nathan.

----- Forwarded by Nathan J Isotalo/HC-SC/GC/CA on 2011-03-30 04:12 PM -----

From: Nathan J Isotalo/HC-SC/GC/CA
To: Evelyn Soo/HC-SC/GC/CA@HWC
Date: 2011-03-30 04:12 PM
Subject:

Hi Evelyn

do you still handle the status reports... do you have any on MDPV? Nathan.

Nathan Isotalo.

Mr. Nathan Isotalo
Sr. Policy Analyst
Regulatory Policy Division
Office of Controlled Substances
Controlled Substances Tobacco Directorate
HECS Health Canada
Tel. (613) 946-4225



Re: Fw: mephedrone □
Nathan J Isotalo to: Evelyn Soo

2011-04-01 07:20 AM

Thank you, Evelyn. Nathan.

Mr. Nathan Isotalo
Sr. Policy Analyst
Regulatory Policy Division
Office of Controlled Substances
Controlled Substances Tobacco Directorate
HECS Health Canada
Tel. (613) 946-4225

Evelyn Soo Hi Nathan As discussed, I am attaching a copy . 2011-03-31 04:11:21 PM

From: Evelyn Soo/HC-SC/GC/CA
To: Nathan J Isotalo/HC-SC/GC/CA@HWG
Date: 2011-03-31 04:11 PM
Subject: Re: Fw: mephedrone

Hi Nathan

As discussed, I am attaching a copy of the status report for mephedrone. I have to update my database but will forward a copy along to you as well as a link to the L:\ drive to facilitate your future searches.

Thanks for your patience.

Evelyn

[attachment "C-4-Methylmethcathinone_mephedrone.wpd" deleted by Nathan J Isotalo/HC-SC/GC/CA]

Evelyn C Soo, PhD
A/Manager, Research on Tobacco | Gestionnaire intérimaire, Recherche sur le tabac
Office of Research and Surveillance | Bureau de la recherche et de la surveillance
Healthy Environments and Consumer Safety Branch (HECSB) | Direction générale de la santé
environnementale et de la sécurité des consommateurs (DGSESC)
Health Canada | Santé Canada
123 Slater St. Ottawa ON K1A 0K9 | 123 rue Slater Ottawa ON K1A 0K9
evelyn.soo@hc-sc.gc.ca
Telephone | Téléphone 613-954-1758
Government of Canada | Gouvernement du Canada

Nathan J Isotalo Thank you, Evelyn...do you have one for mephe... 2011-03-31 09:30:27 AM

Nathan J Isotalo Hi Evelyn do you still handle the status reports. . . 2011-03-30 04:12:28 PM



STATUS DECISION OF CONTROLLED AND NON-CONTROLLED SUBSTANCE(S)

Substance: 3',4'-Methylenedioxy-alpha-pyrrolidinopentanophenone

Based on the current information available to the Office of Controlled Substances, it appears that the above substance is:

Controlled
Not Controlled

under the schedules of the *Controlled Drugs and Substances Act* (CDSA) for the following reason(s):

- 3',4'-Methylenedioxy-alpha-pyrrolidinopentanophenone shares a basic structural element with several controlled substances. These include cathinone, methcathinone, diethylpropion, phenmetrazine and pyrovalerone. The listings of these substances on the schedules to the CDSA are not extended by phrases that would include 3',4'-methylenedioxy-alpha-pyrrolidinopentanophenone.

Supporting document(s) attached: X (Drug Status Report by Mr. LeBelle)

Prepared by: _____ Date: June 27, 2006
Xiao Peng Feng

Drug Status Report by: Mr. Mike LeBelle Date: June 27, 2006

Approved by: _____ Date: _____
DIRECTOR, OFFICE OF
CONTROLLED SUBSTANCES

Drug Status Report

Drug: 3',4'-Methylenedioxy-alpha-pyrrolidinopentanophenone

Drug Name Status: 3',4'-methylenedioxy-alpha-pyrrolidinopentanophenone is the common name

Other Names: 3,4-Methylenedioxy-2-(1-pyrrolidinyl)valerophenone

Chemical Name: 1-(2H-benzo[3,4-d]1,3-dioxol-5-yl)-2-pyrrolidinylpentan-1-one

Chemical structure:



Molecular Formula: C₁₆H₂₁NO₃


Pharmacological/chemical class / Application: unknown


International status:

US: The substance is not listed on the US Controlled Substances Act and is not mentioned on the DEA website.


United Nations: The substance is not listed on the Yellow List - List of Narcotic Drugs under International Control nor the Green List - List of Psychotropic Substances under International Control.

Canadian Status: 3',4'-Methylenedioxy-alpha-pyrrolidinopentanophenone shares a basic structural element with several controlled substances. These include cathinone, methcathinone, diethylpropion, phenmetrazine and pyrovalerone.





Phenmetrazine



Pyrovalerone

The listings of these substances on the schedules to the CDSA are not extended by phrases that would include 3',4'-methylenedioxy-alpha-pyrrolidinopentanophenone.

Recommendation: 3',4'-Methylenedioxy-alpha-pyrrolidinopentanophenone is not included in the schedules to the CDSA and is not a controlled substance.

June 27, 2006

Drug Status Report




Drug: 4-Methylmethcathinone

Drug Name Status: 4-Methylmethcathinone is the common name

Other Names: Mephedrone; 2-methylamino-1-p-tolylpropan-1-one

Chemical Name: 2-Methylamino-1-(4-methylphenyl)-1-propanone

Chemical structure:



Molecular Formula: C₁₁H₁₅NO

Pharmacological class / Application: stimulant

International status:

US: The substance is not currently listed on the US Controlled Substances Act and is not mentioned on the DEA website. However, 4-methylmethcathinone is controlled¹ in the US due to the analogue provisions in the CSA.

United Nations: The substance is not listed on the Yellow List - List of Narcotic Drugs under International Control nor the Green List - List of Psychotropic Substances under International Control.

Canadian Status: Item 1 of Schedule III to the CDSA is, "Amphetamines, their salts, derivatives, isomers and analogues and salts of derivatives, isomers and analogues." Although not listed specifically in item 1 of Schedule III, 4-methylmethamphetamine (structure above) is an amphetamine. 4-Methylmethcathinone is analogous to 4-methylmethamphetamine in that it contains the same structure with an additional oxygen. 4-Methylmethcathinone is therefore an analogue of 4-methylmethamphetamine and is included in item 1 of Schedule III to the CDSA.


A similar rationale was used to recommend that 2-methylamino-1-(3,4-methylenedioxy)-propiophenone be included in item 1 of Schedule III. That report is appended for information.

¹ http://www.usdoj.gov/dea/programs/forensicsci/microgram/journal_v5_num14/pg1.html

The substance is also structurally similar to 2-methylamino-1-phenyl-1-propanone (methcathinone) which is listed as item 21 of Schedule III to the CDSA.

Recommendation: 4-Methylmethcathinone is included in item 1 of Schedule III to the CDSA and is a controlled substance.

June 19, 2008



Re: status reports

Evelyn Soo to: Nathan Isotalo

History: This message has been replied to.

2012-03-09 10:06 AM

Absolutely!

This was done way before my time but it has to be approved before status information is released.

Thanks
Evelyn

Evelyn C Soo, PhD
A/Manager, Research on Tobacco | Gestionnaire intérimaire, Recherche sur le tabac
Office of Research and Surveillance | Bureau de la recherche et de la surveillance
Healthy Environments and Consumer Safety Branch (HECSB) | Direction générale de la santé
environnementale et de la sécurité des consommateurs (DGSESC)
Health Canada | Santé Canada
123 Slater St. Ottawa ON K1A 0K9 | 123 rue Slater Ottawa ON K1A 0K9
evelyn.soo@hc-sc.gc.ca
Telephone | Téléphone 613-954-1758
Government of Canada | Gouvernement du Canada

Nathan Isotalo Hi Evelyn, was the MDPV status report ever ap... 2012-03-08 03:13:04 PM

From: Nathan Isotalo/HC-SC/GC/CA
To: Evelyn Soo/HC-SC/GC/CA@HWC
Date: 2012-03-08 03:13 PM
Subject: Re: status reports

Hi Evelyn,

was the MDPV status report ever approved? Nathan.

Evelyn Soo Here you are. Let me know if you have any ques... 2012-03-08 03:00:03 PM

From: Evelyn Soo/HC-SC/GC/CA
To: Nathan Isotalo/HC-SC/GC/CA@HWC
Cc: Vincent Marleau/HC-SC/GC/CA@HWC
Date: 2012-03-08 03:00 PM
Subject: Re: status reports

Here you are.

Let me know if you have any questions.

Evelyn

[attachment "Mephedrone Drug Status Report pdf" deleted by Nathan Isotalo/HC-SC/GC/CA] [attachment "NC-3',4'-Methylenedioxy-alpha-pyrrolidinopentanophenone (MDPV) 2006-06-27.wpd" deleted by Nathan Isotalo/HC-SC/GC/CA]

Evelyn C Soo, PhD
A/Manager, Research on Tobacco | Gestionnaire intérimaire, Recherche sur le tabac

Office of Research and Surveillance | Bureau de la recherche et de la surveillance
Healthy Environments and Consumer Safety Branch (HECSB) | Direction générale de la santé
environnementale et de la sécurité des consommateurs (DGSESC)
Health Canada | Santé Canada
123 Slater St. Ottawa ON K1A 0K9 | 123 rue Slater Ottawa ON K1A 0K9
evelyn.soo@hc-sc.gc.ca
Telephone | Téléphone 613-954-1758
Government of Canada | Gouvernement du Canada

Nathan Isotalo Hi Evelyn could you please provide the status re.. 2012-03-08 02:57:53 PM

From: Nathan Isotalo/HC-SC/GC/CA
To: Evelyn Soo/HC-SC/GC/CA@HWC
Date: 2012-03-08 02:57 PM
Subject: status reports

Hi Evelyn

could you please provide the status reports for 3,4-methylenedioxypyrovalerone (MPDV) and mephedrone. Thank you. Nathan.



Re: QP - Bath Salts

Andria Sherstone to: Jocelyn Kula, Johanne Beaulieu

Cc: CSTD-DGO

2012-03-02 07:06 AM

I think we can use the QP already in the database.

Jocelyn Kula

Andria. DAS in RAPB may need to be involved...

2012-03-02 07:01 AM EST

From: Jocelyn Kula
To: Andria Sherstone; Johanne Beaulieu
Cc: CSTD-DGO
Date: 2012-03-02 07:01 AM EST
Subject: Re: QP - Bath Salts

Andria. DAS in RAPB may need to be involved if there is any issue to do with testing.

JK

Sent by blackberry

Andria Sherstone Heads up.

2012-03-02 06:57 AM EST

From: Andria Sherstone
To: Johanne Beaulieu; Jocelyn Kula
Cc: CSTD-DGO
Date: 2012-03-02 06:57 AM EST
Subject: Re: QP - Bath Salts

Heads up.

Linsey Hollett

Early heads up - QP request coming shortly af...

2012-03-02 06:50 AM EST

From: Linsey Hollett
To: Andria Sherstone
Cc: Ian Hobler
Date: 2012-03-02 06:50 AM EST
Subject: Fw: QP - Bath Salts

Early heads up - QP request coming shortly after 7. See below.

L

Samy Agha

----- Original Message -----

From: Samy Agha
Sent: 2012-03-02 06:41 AM EST
To: Nadia Biasotto
Cc: Linsey Hollett
Subject: QP - Bath Salts

Good Morning Nadia, MO is seeking a QP note on the article below.

I'm assuming its a HECSB issue, giving it refers to a consumer product, chemicals, and controlled substances.

It also refer to HC officials that conducted tests.

I'll send this out in the official request soon but if it's blatantly not HECSB let me know.

Thanks

Samy

PUBLICATION: The Ottawa Sun

DATE: 2012.03.02

EDITION: Final

SECTION: News

PAGE: 3

ILLUSTRATION: Bath salt Bag seized in Arnprior

BYLINE: DANIELLE BELL, OTTAWA SUN

WORD COUNT: 377

CIRCULATION: 40919

It has nothing to do with a soothing soak in the tub, instead bath salts are the disturbing new designer drug surfacing in the Ottawa area.

Police seized \$200,000 of the hallucinogenic drug from a home near Arnprior last week, while officers in another small Ontario town were shocked when they dealt with people high on the drug for the first time this year. "It's unbelievable how big this problem could become," said OPP drug enforcement Det. Sgt. Paul Henry.

"What's even more scary is young people in the area are probably exposed to this stuff and willing to consume it because it can be legal."

Part of the problem, say police, is the drug makeup is so new **Health Canada** has yet to classify some of the chemicals that can be used to make bath salts -- such as methylenedioxypyrovalerone (MDPV) -- as controlled substances. And they don't show up on drug tests.

Several states have moved to ban the synthetic powder, where U.S. reports describe horror stories of users stabbing themselves and others arming themselves with shotguns to ward off imaginary attackers. "The problem is there seem to be fatalities with first-time users," said Ottawa Hospital toxicologist Dr. Andrew Gee, who has yet to see a case.

"It's not your beginner drug, but it's being touted as that." Sold under such names as "Ivory Wave" or "Vanilla Sky," bath salts are cheap and can be legally ordered

online. They can be smoked, snorted or injected, with effects similar to methampetamines and cocaine.

Ottawa police are monitoring the substance.

"It's just a matter of time," said Staff Sgt. Michael Laviolette, of the Ottawa Police drug unit. "We expect to see it, like every other municipality."

In the Arnprior raid, 2 kg. of suspected bath salts were confiscated after cops raided a date-rape drug lab.

In Owen Sound, hospital staff alerted police when several men with extreme paranoia and hallucinations showed up in one day in late January.

Bath salts, which police later seized in separate busts, was the suspected culprit.

"I'd never seen anything like this," said Owen Sound Det. Sgt. Mark Kielb. "We're concerned."

Health Canada officials test suspected drugs seized by police, but aren't aware of widespread use of bath salts.

Samy Agha

Parliamentary Relations Officer / Agent des relations parlementaires
Cabinet & Parliamentary Affairs Division / Division des affaires du cabinet et parlementaires
Strategic Policy Branch / Direction générale de la politique stratégique

Health Canada / Santé Canada

Samy.Agha@hc-sc.gc.ca

613-952-7108



Bath Salts

Andria Sherstone to: Johanne Beaulieu
Cc: CSTD-OCS-DO, Denis Arsenault

2012-03-02 10:12 AM

Hi Johanne,

Further to your conversation with Cathy this morning, please have the following information on bath salts to DGO no later than 2:00 today:

- What are the ingredients found in bath salts (understand the caveat that we only have the information on what has been seized so far)?
- What is mephedrone?
- What is MDPV?
- Why is mephedrone scheduled and MDPV not?
- How does MDPV fit into the criteria for scheduling?

Let me know if you have any questions.

Thanks!

-A

Andria Sherstone
DGO Advisor / Conseillère
Controlled Substances and Tobacco Directorate / Direction des substances contrôlées et de la lutte au tabagisme
Healthy Environments and Consumer Safety Branch / Direction générale de la santé environnementale et de la sécurité des consommateurs
Health Canada / Santé Canada
Tel: (613) 948-8951

Bath Salts

Andria Sherstone to: Johanne Beaulieu
Cc: Denis Arsenault, CSTD-OCS-DO

2012-03-02 12:49 PM

Hi all,

I need the requested answers by 1:00 in order for Cathy to review in advance of her meeting with MO.

Andria Sherstone
DGO Advisor / Conseillère
Controlled Substances and Tobacco Directorate / Direction des substances contrôlées et de la lutte au
tabagisme
Healthy Environments and Consumer Safety Branch / Direction générale de la santé environnementale et
de la sécurité des consommateurs
Health Canada / Santé Canada
Tel: (613) 948-8951

Backpocket note - MDPV
Andria Sherstone to: Ian Hobler

2012-03-02 02:01 PM



MDPV.doc

Andria Sherstone
DGO Advisor / Conseillère
Controlled Substances and Tobacco Directorate / Direction des substances contrôlées et de la lutte au
tabagisme
Healthy Environments and Consumer Safety Branch / Direction générale de la santé environnementale et
de la sécurité des consommateurs
Health Canada / Santé Canada
Tel: (613) 948-8951

DRAFT – March 2, 2012

Mephedrone and MDPV in Bath Salts

What are the ingredients found in bath salts?

Preliminary reports indicate that the psychoactive ingredients contained in “bath salts” products include mephedrone and/or MDPV.

From January 2010 up until now, Health Canada’s Drug Analysis Service (DAS) has tested 332 exhibits found to contain MDPV or mephedrone. A significant proportion of these exhibits have been found to contain MDPV alone. It must be emphasized, however, that DAS has no way of verifying whether these samples are from “bath salt” products or from other street drugs.

Media coverage on this issue has been limited and does not point to widespread use of bath salts in the general population.

What is mephedrone?

Mephedrone is a synthetic amphetamine-type stimulant also known as 4-methylmethcathinone. It is regulated as a controlled substance because it is an analog of amphetamine (specifically, 4-methylmethamphetamine), which is included in Schedule III to the *Controlled Drugs and Substances Act (CDSA)*.

What is MDPV?

MDPV, also known as 3,4-methylenedioxypyrovalerone, is a synthetic substance related to mephedrone. It is a potent stimulant.

Why is mephedrone scheduled and MDPV not?

Health Canada has not been aware of any widespread marketing or use in Canada of “bath salts” products containing MDPV and/or mephedrone. As such, the presence of such products containing MDPV is an emerging issue and we are still collecting preliminary information so that we can make an informed decision as to whether to initiate a scheduling assessment. Mephedrone, meanwhile, is already a controlled substance in Canada as it has been deemed an analog of amphetamine which is listed under Schedule III to the CDSA.

How does MDPV fit into the criteria for scheduling?

CDSA Scheduling Factor	Preliminary Assessment of MDPV
International requirements and trends in control	<ul style="list-style-type: none">Not controlled internationally.Preliminary analysis indicates that various levels of control have been placed on MDPV in the United States, United Kingdom, Denmark, Ireland, Finland and Sweden.
Chemical and/or pharmacological similarity to substances listed in	<ul style="list-style-type: none">Structurally, MDPV appears to show some similarity to both mephedrone and

DRAFT – March 2, 2012

CDSA	amphetamine; further detailed analysis of the chemistry and pharmacology of MDPV needs to be conducted.
Legitimate therapeutic, scientific or industrial use	<ul style="list-style-type: none">• No drug products containing MDPV have been approved for sale in Canada. Preliminary research does not suggest any legitimate industrial or scientific uses
Potential for abuse and/or addiction liability	<ul style="list-style-type: none">• An assessment of the abuse and/or addiction liability of MDPV has yet to be conducted.
Evidence of extent of actual abuse	<ul style="list-style-type: none">• Media reports have emerged that MDPV is being used for its stimulant properties. However, no assessment has been conducted as of yet regarding the actual extent of abuse of MDPV in Canada.
Risk to personal and/or public health and safety	<ul style="list-style-type: none">• While little is known about the specific health effects of MDPV, the use of stimulants in general may significantly increase blood pressure, as well as heart and breathing rate. Their use has also been associated with severe panic attacks and anxiety, as well as hallucinations.• DAS has identified MDPV and/or mephedrone in 332 exhibits tested since January 2010. DAS cannot verify, however, whether these samples are from “bath salt” products or from other street drugs.



Fw: Backpocket note - MDPV
Andria Sherstone to: Johanne Beaulieu
Cc: CSTD-OCS-DO, Denis Arsenault

2012-03-02 02:04 PM

Hi all,

Please see the DG approved version below. Note that one sentence on media coverage was added.



MDPV.doc

Andria Sherstone
DGO Advisor / Conseillère
Controlled Substances and Tobacco Directorate / Direction des substances contrôlées et de la lutte au
tabagisme
Healthy Environments and Consumer Safety Branch / Direction générale de la santé environnementale et
de la sécurité des consommateurs
Health Canada / Santé Canada
Tel: (613) 948-8951

DRAFT – March 2, 2012

Mephedrone and MDPV in Bath Salts

What are the ingredients found in bath salts?

Preliminary reports indicate that the psychoactive ingredients contained in “bath salts” products include mephedrone and/or MDPV.

From January 2010 up until now, Health Canada’s Drug Analysis Service (DAS) has tested 332 exhibits found to contain MDPV or mephedrone. A significant proportion of these exhibits have been found to contain MDPV alone. It must be emphasized, however, that DAS has no way of verifying whether these samples are from “bath salt” products or from other street drugs.

Media coverage on this issue has been limited and does not point to widespread use of bath salts in the general population.

What is mephedrone?

Mephedrone is a synthetic amphetamine-type stimulant also known as 4-methylmethcathinone. It is regulated as a controlled substance because it is an analog of amphetamine (specifically, 4-methylmethamphetamine), which is included in Schedule III to the *Controlled Drugs and Substances Act (CDSA)*.

What is MDPV?

MDPV, also known as 3,4-methylenedioxypyrovalerone, is a synthetic substance related to mephedrone. It is a potent stimulant.

Why is mephedrone scheduled and MDPV not?

Health Canada has not been aware of any widespread marketing or use in Canada of “bath salts” products containing MDPV and/or mephedrone. As such, the presence of such products containing MDPV is an emerging issue and we are still collecting preliminary information so that we can make an informed decision as to whether to initiate a scheduling assessment. Mephedrone, meanwhile, is already a controlled substance in Canada as it has been deemed an analog of amphetamine which is listed under Schedule III to the CDSA.

How does MDPV fit into the criteria for scheduling?

CDSA Scheduling Factor	Preliminary Assessment of MDPV
International requirements and trends in control	<ul style="list-style-type: none">• Not controlled internationally.• Preliminary analysis indicates that various levels of control have been placed on MDPV in the United States, United Kingdom, Denmark, Ireland, Finland and Sweden.
Chemical and/or pharmacological similarity to substances listed in	<ul style="list-style-type: none">• Structurally, MDPV appears to show some similarity to both mephedrone and

DRAFT – March 2, 2012

CDSA	amphetamine; further detailed analysis of the chemistry and pharmacology of MDPV needs to be conducted.
Legitimate therapeutic, scientific or industrial use	<ul style="list-style-type: none">No drug products containing MDPV have been approved for sale in Canada. Preliminary research does not suggest any legitimate industrial or scientific uses
Potential for abuse and/or addiction liability	<ul style="list-style-type: none">An assessment of the abuse and/or addiction liability of MDPV has yet to be conducted.
Evidence of extent of actual abuse	<ul style="list-style-type: none">Media reports have emerged that MDPV is being used for its stimulant properties. However, no assessment has been conducted as of yet regarding the actual extent of abuse of MDPV in Canada.
Risk to personal and/or public health and safety	<ul style="list-style-type: none">While little is known about the specific health effects of MDPV, the use of stimulants in general may significantly increase blood pressure, as well as heart and breathing rate. Their use has also been associated with severe panic attacks and anxiety, as well as hallucinations.DAS has identified MDPV and/or mephedrone in 332 exhibits tested since January 2010. DAS cannot verify, however, whether these samples are from "bath salt" products or from other street drugs.



Fw: QP on MDPV
Andria Sherstone to: Johanne Beaulieu

2012-03-02 04:32 PM

Et voilà!

Andria Sherstone
DGO Advisor / Conseillère
Controlled Substances and Tobacco Directorate / Direction des substances contrôlées et de la lutte au
tabagisme
Healthy Environments and Consumer Safety Branch / Direction générale de la santé environnementale et
de la sécurité des consommateurs
Health Canada / Santé Canada
Tel: (613) 948-8951

----- Forwarded by Andria Sherstone/HC-SC/GC/CA on 2012-03-02 04:32 PM -----

From: Nadia Biasotto/HC-SC/GC/CA
To: Andria Sherstone/HC-SC/GC/CA@HWC, Ian Hobler/HC-SC/GC/CA@HWC
Date: 2012-03-02 02:25 PM
Subject: QP on MDPV

MDPV

Nadia Biasotto
Office of the Assistant Deputy Minister / Bureau du sous-ministre adjoint
Healthy Environments and Consumer Safety Branch / Direction Générale, Santé
Environnementale et Sécurité des Consommateurs
Executive Services / Services Exécutifs
Health Canada / Santé Canada

Tel | Tél : (613) 960-4700
Fax | Téléc : (613) 946-6666
E-mail | Courriel : nadia.biasotto@hc-sc.gc.ca

**QUESTION PERIOD NOTE
NOTE POUR LA PÉRIODE DE
QUESTIONS**

Date:	March 2, 2012
Classification :	HECS PROTECTED - SESC PROTÉGÉ

English:

MDPV AND MEPHEDRONE IN BATH SALTS

SYNOPSIS - SOMMAIRE

English:

There has been recent media attention on the use of "bath salts" as stimulants. Such "bath salts" have been found to contain MDPV (3,4-methylenedioxypyrovalerone) or mephedrone. Such products are likely labelled as "bath salts" in order to appear legal. Mephedrone is considered a controlled substance in Canada, while MDPV is not. Health Canada is not aware of widespread use or marketing of these products in Canada, but will take further action if required.

ANTICIPATED QUESTION - QUESTION PRÉVUE

English:

What is the Government doing about MDPV and Mephedrone in bath salts?

English:

- This government is very concerned about the recent seizure of so-called "bath salts" containing a substance called MDPV.
- Health Canada officials will be working with law enforcement agencies to determine the most appropriate steps to take to ensure that MDPV is controlled in Canada.
- This Government is committed to controlling substances that produce harm to health and to society when abused.

Français:

BACKGROUND - CONTEXTE

English:

A number of recent media articles in both the United States and Canada have highlighted dangers posed by products labelled and marketed as "bath salts" which are being used as a stimulant.

Genuine bath salt products are composed of water soluble mineral salts and are added to water for the purpose of cleansing, softening and/or perfuming the skin. The packages of "bath salts" being used as a stimulant contain ingredients such as MDPV and/or mephedrone. Such products are sold, for example, at convenience stores, smoke shops, gas stations, and online. No drug products containing MDPV and/or mephedrone have been approved for sale in Canada. Regular bath salts do not contain these substances.

Since January 2010, 280 samples received by Health Canada's Drug Analysis Service (DAS) were found to contain MDPV. Of the two substances in question, only mephedrone is a controlled substance under the *Controlled Drugs and Substances Act* (CDSA). MDPV is not a controlled substance, but the department will be working with law enforcement agencies to determine the most appropriate steps to take to ensure that MDPV is controlled in Canada.

The CDSA prohibits all activities, e.g., possession, production, distribution, sale, import, and/or export, involving substances listed in one of the Schedules to the Act, unless authorized by regulation. Health Canada considers

several factors in determining whether the scheduling of a substance under the Controlled Drugs and Substances Act (CDSA) is warranted. These include:

- Overall risk to public health and safety posed by the substance;
- Chemical and pharmacological similarity to other substances already regulated under the CDSA;
- Legitimate uses of the substance (i.e., therapeutic, industrial or commercial);
- Potential for abuse and risk of addiction associated with the substance;
- Extent of actual abuse of the substance in Canada and internationally; and
- International requirements and trends in international control.

Health Canada will continue to examine this issue and take further action if deemed necessary.

Mephedrone is an analogue of amphetamine and is thus included in Schedule III to the CDSA. Adverse effects associated with the use of amphetamines can include seizures, cerebral hemorrhage, high fever, coma or death.

MDPV is a central nervous system stimulant whose use can cause increased blood pressure and increased heart rate. The use of MDPV has also been associated with panic attacks, anxiety and hallucinations. MDPV is not regulated as a controlled substance in Canada.

In the United States, the Drug Enforcement Administration has recently used its emergency scheduling authority to temporarily ban mephedrone, MDPV and methylone. MDPV has also recently been banned in the United Kingdom.

No drug products containing MDPV or mephedrone have been approved for sale in Canada.

ATTACHMENTS / PIÈCE(S)-JOINTE(S)

Contact/Personne ressource : Jocelyn Kula/HC-SC/GC/CA	Tel. no./No de tél. 944-0125	Approved by/ Approuvé par Hilary Geller, ADM (HECS/SESC)	Tel. no./No. de tél. 946-6701
	Mobile/ Cellulaire: 613-797-2103	Title/ Titre:	Mobile/ Cellulaire:
Alternate/ Secondaire: Denis Arsenault	Telephone/ Téléphone: 957-6828		
	Mobile/ Cellulaire:		

Date Prepared/Préparé le : 2011-07-21

Prepared by/Préparé par : Angela Doyle **Phone/ No de tél. :** 954-6792

Office/Bureau : CSTD - Office of Controlled Substances

**Date Contact Signed/
Signature de la personne
ressource :** 2012-03-02

Contact Signed - Signé

**D.G. Verification/
Vérification par le D.E. :** Cathy Sabiston

D.G. Approved / Approuvé D.E.

Date D.G. Verified/ 2012-03-02
Date vérifié par le D.E. :

Programme : Controlled Substances and Tobacco Directorate

ADM Approved/ Approbation Hilary Geller, ADM (HECS/SESC)
par le SMA : (946-6701)

Branch/ Direction générale : HECS/SESC

Department/ Ministère : Health Canada / Santé Canada



Fw: Backpocket note - MDPV
Andria Sherstone to: Cathy A Sabiston

2012-03-05 12:08 PM

FYI - have requested Johanne's group get working on this now.

Andria Sherstone
DGO Advisor / Conseillère
Controlled Substances and Tobacco Directorate / Direction des substances contrôlées et de la lutte au tabagisme
Healthy Environments and Consumer Safety Branch / Direction générale de la santé environnementale et de la sécurité des consommateurs
Health Canada / Santé Canada
Tel: (613) 948-8951

----- Forwarded by Andria Sherstone/HC-SC/GC/CA on 2012-03-05 12:08 PM -----

From: Ian Hobler/HC-SC/GC/CA
To: Andria Sherstone/HC-SC/GC/CA@HWC
Date: 2012-03-05 11:52 AM
Subject: Re: Fw: Backpocket note - MDPV

Hi Andria.

I went through the QP and the back pocket note with Hilary and she had some questions/changes she would like to see before anything goes up.

For the Back Pocket Note:

1. How come we don't know if samples are coming from bath salts or not? Who would make that determination (law enforcement)?
2. Could we get some more detail on the DAS results? How many DAS samples contained MDPV only? Mephedrone only?
3. Is it still the case that all bath salts contain mephedrone and MDPV, and that law enforcement can take action based on the presence of mephedrone in bath salts?
4. Can we expand on the note to include:
 - who has OCS been working with on the issue of bath salts?
 - what steps have been taken to date to address bath salts (mephedrone and MDPV)?
 - what next steps are being taken/considered?
 - what are the timings for the above?

For the QP: Could you please ensure the background is aligned with info the back pocket note (e.g DAS stats, ability for law enforcement to take action based on the presence of mephedrone, etc.)

Once this comes up, Hilary may want to schedule a quick call with OCS to go through how MO will be briefed.

Could you please get this up ASAP? I'll attempt to get an extension from DMO for the end of day today for this material.

Thanks.
Ian

Andria Sherstone Sorry, use this version instead. 2012-03-02 02:04:37 PM

From: Andria Sherstone/HC-SC/GC/CA
To: Ian Hobler/HC-SC/GC/CA@HWC
Date: 2012-03-02 02:04 PM
Subject: Fw: Backpocket note - MDPV

Sorry, use this version instead.

[attachment "MDPV.doc" deleted by Ian Hobler/HC-SC/GC/CA]

Andria Sherstone
DGO Advisor / Conseillère
Controlled Substances and Tobacco Directorate / Direction des substances contrôlées et de la lutte au tabagisme
Healthy Environments and Consumer Safety Branch / Direction générale de la santé environnementale et de la sécurité des consommateurs
Health Canada / Santé Canada
Tel: (613) 948-8951

----- Forwarded by Andria Sherstone/HC-SC/GC/CA on 2012-03-02 02:04 PM -----

From: Andria Sherstone/HC-SC/GC/CA
To: Ian Hobler/HC-SC/GC/CA@HWC
Date: 2012-03-02 02:01 PM
Subject: Backpocket note - MDPV

[attachment "MDPV.doc" deleted by Andria Sherstone/HC-SC/GC/CA]

Andria Sherstone
DGO Advisor / Conseillère
Controlled Substances and Tobacco Directorate / Direction des substances contrôlées et de la lutte au tabagisme
Healthy Environments and Consumer Safety Branch / Direction générale de la santé environnementale et de la sécurité des consommateurs
Health Canada / Santé Canada
Tel: (613) 948-8951



Daime Tea and Bath Salts
Andria Sherstone to: Jocelyn Kula
Cc: CSTD-OCS-DO, Denis Arsenault

2012-03-05 03:09 PM

ADMO is asking for both revised documents. Please advise when DGO can expect them.

Thanks!
-A

Andria Sherstone
DGO Advisor / Conseillère
Controlled Substances and Tobacco Directorate / Direction des substances contrôlées et de la lutte au
tabagisme
Healthy Environments and Consumer Safety Branch / Direction générale de la santé environnementale et
de la sécurité des consommateurs
Health Canada / Santé Canada
Tel: (613) 948-8951

s.21f(1)(a)

s.21(1)(b)



Re: Bath Salts

Andria Sherstone to: Cathy A Sabiston

2012-03-06 10:33 AM

Sounds good. Just an FYI - ADMO has been asking about this revised version this morning. I will let Ian know it will be early this afternoon.

Andria Sherstone
DGO Advisor / Conseillère
Controlled Substances and Tobacco Directorate / Direction des substances contrôlées et de la lutte au tabagisme
Healthy Environments and Consumer Safety Branch / Direction générale de la santé environnementale et de la sécurité des consommateurs
Health Canada / Santé Canada
Tel: (613) 948-8951

Cathy A Sabiston Ok let's go thru this on the margins of the instru... 2012-03-06 10:30:00 AM

From: Cathy A Sabiston/HC-SC/GC/CA
To: Andria Sherstone/HC-SC/GC/CA@HWC
Cc: Johanne Beaulieu/HC-SC/GC/CA@HWC, Jocelyn Kula/HC-SC/GC/CA@HWC
Date: 2012-03-06 10:30 AM
Subject: Re: Bath Salts

Ok let's go thru this on the margins of the instru delgn mtg this aft.

Andria Sherstone Hi Cathy. Below please find the revised Bath... 2012-03-06 09:59 AM EST

From: Andria Sherstone
To: Cathy A Sabiston
Cc: Johanne Beaulieu; Jocelyn Kula
Date: 2012-03-06 09:59 AM EST
Subject: Bath Salts

Hi Cathy,

Below please find the revised Bath Salts fact sheet as per HG's comments. All of the comments have been made, except for those that requested clarity on next steps and timing.

I spoke to Jo yesterday about what she plans to speak to MO about. I will get additional information from her this morning.

-A

Mephedrone and MDPV in Bath Salts

What are the ingredients found in bath salts?

Preliminary reports indicate that the psychoactive ingredients contained in "bath salts" products include mephedrone and/or MDPV.

Media coverage on this issue has been limited and does not point to widespread use of “bath salt” products in the general population.

From January 2010 up until now, Health Canada’s Drug Analysis Service (DAS) has tested 332 exhibits found to containing MDPV or mephedrone. 315 of these exhibits were found to contain MDPV alone; in fact, only 17 were found to contain mephedrone.

It must be emphasized, however, that DAS has no way of verifying whether these samples are from “bath salt” products or from other street drugs. When submitting exhibits for testing, law enforcement agencies are not required to provide DAS with any information as to the source or product a sample was taken from. As a result, DAS would never be able to attest to the fact that a given sample found to contain MDPV came specifically from a seizure of “bath salts”. It may be possible, however, for law enforcement agencies to make a linkage between a given seizure of “bath salt” products and positive results for MDPV found in analyses conducted by DAS.

In those cases where these products have been found to contain mephedrone, law enforcement agencies can take action as mephedrone is already considered to be a controlled substance under the *Controlled Drugs and Substances Act* (CDSA).

What is mephedrone?

Mephedrone is a synthetic amphetamine-type stimulant also known as 4-methylmethcathinone. It is regulated as a controlled substance because it is an analog of amphetamine (specifically, 4-methylmethamphetamine), which is included in Schedule III to the CDSA.

What is MDPV?

MDPV, also known as 3,4-methylenedioxypyrovalerone, is a synthetic substance related to mephedrone. It is a potent stimulant.

Why is mephedrone scheduled and MDPV not?

Health Canada has not been aware of any widespread marketing or use in Canada of “bath salt” products containing MDPV and/or mephedrone. As there is no evidence of a significant presence of products containing MDPV in Canada, we are still collecting preliminary information. Mephedrone, meanwhile, is already a controlled substance in Canada as it has been deemed an analog of amphetamine which is listed under Schedule III to the CDSA.

How does MDPV fit into the criteria for scheduling?

CDSA Scheduling Factor	Preliminary Assessment of MDPV
International requirements and trends in control	<ul style="list-style-type: none">Not controlled internationally.Preliminary analysis indicates that various levels of control have been placed on MDPV in the United States, United Kingdom, Denmark,

Ireland, Finland and Sweden.	
Chemical and/or pharmacological similarity to substances listed in CDSA	<ul style="list-style-type: none">Structurally, MDPV appears to show some similarity to both mephedrone and amphetamine; further detailed analysis of the chemistry and pharmacology of MDPV needs to be conducted.
Legitimate therapeutic, scientific or industrial use	<ul style="list-style-type: none">No drug products containing MDPV have been approved for sale in Canada. Preliminary research does not suggest any legitimate industrial or scientific uses
Potential for abuse and/or addiction liability	<ul style="list-style-type: none">An assessment of the abuse and/or addiction liability of MDPV has yet to be conducted.
Evidence of extent of actual abuse	<ul style="list-style-type: none">Media reports have emerged that MDPV is being used for its stimulant properties. However, no assessment has been conducted as of yet regarding the actual extent of abuse of MDPV in Canada.
Risk to personal and/or public health and safety	<ul style="list-style-type: none">While little is known about the specific health effects of MDPV, the use of stimulants in general may significantly increase blood pressure, as well as heart and breathing rate. Their use has also been associated with severe panic attacks and anxiety, as well as hallucinations.DAS has identified MDPV and/or mephedrone in 332 exhibits tested since January 2010. DAS cannot verify, however, whether these samples are from "bath salt" products or from other street drugs.

What is the Office of Controlled Substances (OCS) doing regarding the MDPV?

OCS worked with DAS and the Office of Research and Surveillance (CSTD) to confirm the scheduling status of mephedrone and MDPV and to gather preliminary information regarding the number of times they have been seized by law enforcement as suspected controlled substances. OCS remains in contact with the RCMP on this file and will consider developing a work plan regarding the potential scheduling of MDPV should intelligence suggest that the availability of MDPV and/or "bath salt" products warrants further action.

Andria Sherstone
DGO Advisor / Conseillère
Controlled Substances and Tobacco Directorate / Direction des substances contrôlées et de la lutte au
tabagisme
Healthy Environments and Consumer Safety Branch / Direction générale de la santé environnementale et
de la sécurité des consommateurs
Health Canada / Santé Canada
Tel: (613) 948-8951



Fw: MO Request regarding Bath Salts
Louise Bertrand to: Ian Hobler

2012-04-25 12:03 PM

Three main areas of activity for MDPV:

1. We are currently working on our scheduling assessment for MDPV, which includes an external contract for the assessment of pharmacology data (completion Spring 2012).
2. Triage questionnaire in final stages of development.
3. Notice of Intent to Interested Parties in early stages of development.

Let me know if you need anything else.

Louise Bertrand Hi, ADMO just informed me that MO would lik... 2012-04-25 11:49 AM EDT

From: Louise Bertrand
To: Johanne Beaulieu
Cc: Cathy A Sabiston; Andria Sherstone; CSTD-OCS-DO; Jocelyn Kula
Date: 2012-04-25 11:49 AM EDT
Subject: MO Request regarding Bath Salts

Hi,
ADMO just informed me that MO would like to know what CSTD activities are on-going with regards to the assessment of "Bath Salts"/MDPV (e.g. analysis steps, meetings, etc...).

MO is briefing Minister in the next few minutes and wants this info now.

Thanks,
Louise Bertrand
DGO Advisor | Conseillère
Controlled Substances and Tobacco Directorate | Direction des substances contrôlées et de la lutte au tabagisme
Health Canada | Santé Canada
(613) 957-2867



Re: MDPV

Andria Sherstone to: Jocelyn Kula

2012-04-26 11:34 AM

I have two colour charts for regulatory and policy/exemptions. Show the projects, and then the timelines for getting it through to, in the case of the regs, to CGII.

Andria Sherstone
DGO Advisor / Conseillère
Controlled Substances and Tobacco Directorate / Direction des substances contrôlées et de la lutte au tabagisme
Healthy Environments and Consumer Safety Branch / Direction générale de la santé environnementale et de la sécurité des consommateurs
Health Canada / Santé Canada
Tel: (613) 948-8951

Jocelyn Kula Sorry, what is the format that was used for Dec t... 2012-04-26 11:28:48 AM

From: Jocelyn Kula/HC-SC/GC/CA
To: Andria Sherstone/HC-SC/GC/CA@HWC
Date: 2012-04-26 11:28 AM
Subject: Re: MDPV

Sorry, what is the format that was used for Dec to May?
Johanne is not around this morning so I can't ask her.....

Jocelyn Kula
Manager, Regulatory Policy Division/ Gestionnaire, Division de la politique réglementaire
Office of Controlled Substances/ Bureau des substances contrôlées
Healthy Environments and Consumer Safety Branch/ Direction générale de la santé environnementale et de la sécurité des consommateurs
Health Canada/ Santé Canada
Tel: (613) 946-0125 Fax: (613) 946-4224

Andria Sherstone Hi Jo, I spoke with Cathy a little more about the... 2012-04-26 11:26:33 AM

From: Andria Sherstone/HC-SC/GC/CA
To: Johanne Beaulieu/HC-SC/GC/CA@HWC
Cc: Denis Arsenault/HC-SC/GC/CA@HWC, Jocelyn Kula/HC-SC/GC/CA@HWC, Tara Phillips/HC-SC/GC/CA@HWC, CSTD-OCS-DO
Date: 2012-04-26 11:26 AM
Subject: Re: MDPV

Hi Jo,

I spoke with Cathy a little more about the workplan this morning. By May 02, could you also provide a workplan on all OCS' upcoming regulatory projects and policy and exemptions. Ideally, this would be in the same format that OCS used to show what the game plan was for Dec. 2011 to May 2012.

Let me know if you have any questions.

Thanks!

-A

Andria Sherstone
DGO Advisor / Conseillère
Controlled Substances and Tobacco Directorate / Direction des substances contrôlées et de la lutte au tabagisme
Healthy Environments and Consumer Safety Branch / Direction générale de la santé environnementale et de la sécurité des consommateurs
Health Canada / Santé Canada
Tel: (613) 948-8951

Cathy A Sabiston | How about one week from today? 2012-04-25 04:49:07 PM

From: Cathy A Sabiston/HC-SC/GC/CA
To: Johanne Beaulieu/HC-SC/GC/CA@HWC, Jocelyn Kula/HC-SC/GC/CA@HWC, Denis Arsenault/HC-SC/GC/CA@HWC, Tara Phillips/HC-SC/GC/CA@HWC, Andria Sherstone/HC-SC/GC/CA@HWC
Date: 2012-04-25 04:49 PM
Subject: Re: MDPV

How about one week from today?

Johanne Beaulieu | Good Day Cathy. We have one already. Dead... 2012-04-25 04:23 PM EDT

From: Johanne Beaulieu
To: Jocelyn Kula; Denis Arsenault; Tara Phillips; Cathy A Sabiston; Andria Sherstone
Date: 2012-04-25 04:23 PM EDT
Subject: MDPV

Good Day Cathy.

We have one already. Deadlines have been reviewed on the basis of the discussions today.

It will therefore be easy to provide you with this revised workplan.

Do you have a deadline in mind?

Johanne

Cathy A Sabiston

----- Original Message -----

From: Cathy A Sabiston
Sent: 2012-04-25 03:32 PM EDT
To: Johanne Beaulieu
Cc: Andria Sherstone; SoniaH Lindblad1

Given the media reports on mdpv, I would like a formal workplan developed for dgo and admo. Andria, it needs to be added to issues tracking sheet discussed at hecs business planning.

Thx. Cas

MDPV

Andria Sherstone to: Johanne Beaulieu
Cc: SoniaH Lindblad1

2012-05-22 02:00 PM

Hi Johanne,

I noted in the 3 month outlook that OCS will be moving forward with the NOI for MDPV on June 16. Cathy will need to be briefed on the outcome of the scheduling assessment and the overall MDPV workplan.

Sonia, could you please set up a briefing on MDPV for the week of June 4?

Thanks!
-A

Andria Sherstone
DGO Advisor / Conseillère
Controlled Substances and Tobacco Directorate / Direction des substances contrôlées et de la lutte au tabagisme
Healthy Environments and Consumer Safety Branch / Direction générale de la santé environnementale et de la sécurité des consommateurs
Health Canada / Santé Canada
Tel: (613) 948-8951

s.21(1)(a)
s.21(1)(b)



OCS and MDPV Workplans

Andria Sherstone to: Johanne Beaulieu
Cc: CSTD-OCS-DO

2012-05-23 03:51 PM

Hi Johanne,

I have advised Cathy that the workplan for OCS is being revised [REDACTED]. She would like a bootleg copy of the workplan for OCS as a whole by 9 am Friday so that she can take it to her bilat with the ADM. [REDACTED]

Also, could you let me know if the MDPV workplan will be ready for Friday at 9, [REDACTED]

Thanks!
-A

Andria Sherstone
DGO Advisor / Conseillère
Controlled Substances and Tobacco Directorate / Direction des substances contrôlées et de la lutte au tabagisme
Healthy Environments and Consumer Safety Branch / Direction générale de la santé environnementale et de la sécurité des consommateurs
Health Canada / Santé Canada
Tel: (613) 948-8951



URGENT: MO Request - Bath Salts

Andria Sherstone to: Johanne Beaulieu, Jocelyn Kula
Cc: CSTD-DGO, CSTD-OCS-DO

2012-05-24 08:29 AM

Please see the request from MO below.

Please prepare a response to the Qs below in e-mail format.

This is required in DGO no later than 1130 today.

At the same time, please route up the revised bath salts QP requested yesterday, if it has already not been done.

Thanks!

-A

Ian Hobler

----- Original Message -----

From: Ian Hobler
Sent: 2012-05-24 08:14 AM EDT
To: Andria Sherstone
Subject: MO Request - Bath Salts

Hi Andria.

MO has asked for an update on OCS's work on bath salts (MDPV specifically) for today.

Could I please get by mid-afternoon:

1. A brief explanation of what bath salts are and what their ingredients are.
2. How seizure data has indicated that MDPV only bath salts are becoming more prevalent.
3. HC has acted on the data by initiating work to schedule (break down the work in progress e.g. Triage questionnaire, pharmacology assessment, etc. and associated timelines)
4. We are planning to accelerate the scheduling of MDPV like we did for BZP (another designer recreational drug) through an NOI and CGII.
5. Please add in any other details you think would be useful.

I think we can avoid a fully-blown BN to MO if we get this up in time. Please note this is for MO's info on the policy side, not for communication to the public - media lines are still good for that.

Give me a call if you would like to discuss.

Thanks!

Ian



Fw: MDPV - Revisions required
Andria Sherstone to: Johanne Beaulieu

2012-05-24 03:27 PM

Are you fine with the proposed revisions below?

Andria Sherstone
DGO Advisor / Conseillère
Controlled Substances and Tobacco Directorate / Direction des substances contrôlées et de la lutte au tabagisme
Healthy Environments and Consumer Safety Branch / Direction générale de la santé environnementale et de la sécurité des consommateurs
Health Canada / Santé Canada
Tel: (613) 948-8951

----- Forwarded by Andria Sherstone/HC-SC/GC/CA on 2012-05-24 03:27 PM -----

From: Jocelyn Kula/HC-SC/GC/CA
To: Andria Sherstone/HC-SC/GC/CA@HWC
Cc: Johanne Beaulieu/HC-SC/GC/CA@HWC, Tara Phillips/HC-SC/GC/CA@HWC
Date: 2012-05-24 03:06 PM
Subject: Re: MDPV - Revisions required

Hi Andria,

Here are responses to Cathy's comments and questions.

1. A brief explanation of what bath salts are and what their ingredients are.

Over the past several months, there have been increasing media reports on synthetic stimulants sold under the guise of "bath salts" appearing in Canada. Law enforcement and border seizures of products labelled as "bath salts" have also been increasing. Such products are not genuine bath salt products, i.e., epsom salts, intended for softening/cleansing the skin, but contain one or more substances with stimulant properties such as mephedrone and methylone (which are already included in Schedule III to the CDSA as analogues of amphetamine), and 3,4-methylenedioxypyrovalerone (MDPV). MDPV, in particular, is most often sold as a powder and is reported to be administered through a wide range of modalities, with oral ingestion, injection, and nasal insufflation (snorting) being most prevalent. While the extent of their use in Canada is unknown, "bath salts" are available for purchase on the Internet and may be found in alternative lifestyle stores. Examples of product names include "MITSEEZ", "MOJO Novelty Bath Salts", "Ivory Snow", "Purple Wave", and "Vanilla Sky". These products may also be labelled as "plant food" and/or "not for human consumption" to circumvent regulatory control.

CAS comment - do all Bath Salts contain all 3 ingredients (MDPV, Mephedrone, Methylone)? Please clarify.

No. "Bath salts" contain one or more substances with stimulant properties such as MDPV, mephedrone and/or methylone but not necessarily all three. In fact, DAS analysis has not yet identified both MDPV and mephedrone in the same exhibit and has not yet identified methylone in any exhibits. Methylone has however been identified in "bath salt" products in the United States. [Note, that we have now underlined the text "...contain one or more substances....."; feel free to remove if you don't think this is necessary for ADMO]

2. How seizure data has indicated that MDPV only bath salts are becoming more prevalent.

From January 2010 to present, Health Canada's Drug Analysis Service (DAS) has identified MDPV or

mephedrone in 461 exhibits of suspected controlled substances seized by law enforcement. 444 of these exhibits were found to contain MDPV and 17 were found to contain mephedrone.

CAS comment - what about MDPV alone? None of the 444 exhibits identified as MDPV contained mephedrone, and none of the 17 exhibits identified as mephedrone contained MDPV. The reason we did not use the word 'alone' with the MDPV number is because DAS cannot be certain that no other controlled substances were present in the sample.

3.

As part of its scheduling assessment, Health Canada let an external contract aimed at assessing the abuse liability and dependence potential of MDPV. The assessment was completed in May 2012, and concluded that based on MDPV's chemical structure, a similar abuse liability to amphetamine may be expected. In addition, because MDPV can be consumed in a number of different ways and has a short duration of action, it may be more appealing to drug users. With respect to physical dependence and tolerance, there is insufficient evidence on which to base any specific conclusions regarding MDPV at this point in time.

A comprehensive scheduling assessment is now underway with a target timeline of August 2012.

DGO comment - please provide some plain language examples on the assessment of abuse liability and dependence potential. Simply re-word what Tara sent earlier.

To initiate the regulatory process,

Timelines:

June 2012 - publication of *Notice to interested parties* in CGI

August 2012 - NOI comment period ends; submission of drafting instructions to HC drafting service

Fall 2012 - regulatory package preparation and approval

January/February 2013 - publication of regulation in CGII

4. We are planning to accelerate the scheduling of MDPV like we did for BZP (another designer recreational drug) through an NOI and CGII.

Based on the experience with BZP,

5. Please add in any other details you think would be useful.

Canadian media reports have originated primarily from Eastern provinces, including New Brunswick and Nova Scotia. On May 18, 2012, health officials in northern Nova Scotia issued a warning concerning the dangers posed by "bath salts", including reports of cases where use has resulted in the user requiring emergency care.

Jocelyn

Jocelyn Kula

Manager, Regulatory Policy Division/ Gestionnaire, Division de la politique réglementaire

Office of Controlled Substances/ Bureau des substances contrôlées

Healthy Environments and Consumer Safety Branch/ Direction générale de la santé environnementale et de la sécurité des consommateurs

Health Canada/ Santé Canada

Tel: (613) 946-0125 Fax: (613) 946-4224

Andria Sherstone

Please see comments/requested revisions belo...

2012-05-24 02:14:24 PM

From: Andria Sherstone/HC-SC/GC/CA
To: Johanne Beaulieu/HC-SC/GC/CA@HWC
Cc: Jocelyn Kula/HC-SC/GC/CA@HWC, Tara Phillips/HC-SC/GC/CA@HWC, CSTD-OCS-DO
Date: 2012-05-24 02:14 PM
Subject: MDPV - Revisions required

Please see comments/requested revisions below. Please have a revised version to DGO no later than 3:00.

1. A brief explanation of what bath salts are and what their ingredients are.

Over the past several months, there have been increasing media reports on synthetic stimulants sold under the guise of "bath salts" appearing in Canada. Law enforcement and border seizures of products labelled as "bath salts" have also been increasing. Such products are not genuine bath salt products, i.e., epsom salts, intended for softening/cleansing the skin, but contain one or more substances with stimulant properties such as mephedrone and methylone (which are already included in Schedule III to the CDSA as analogues of amphetamine), and 3,4-methylenedioxypyrovalerone (MDPV). MDPV, in particular, is most often sold as a powder and is reported to be administered through a wide range of modalities, with oral ingestion, injection, and nasal insufflation (snorting) being most prevalent. While the extent of their use in Canada is unknown, "bath salts" are available for purchase on the Internet and may be found in alternative lifestyle stores. Examples of product names include "MITSEEZ", "MOJO Novelty Bath Salts", "Ivory Snow", "Purple Wave", and "Vanilla Sky". These products may also be labelled as "plant food" and/or "not for human consumption" to circumvent regulatory control.

CAS comment - do all Bath Salts contain all 3 ingredients (MDPV, Mephedrone, Methylone)? Please clarify.

2. How seizure data has indicated that MDPV only bath salts are becoming more prevalent.

From January 2010 to present, Health Canada's Drug Analysis Service (DAS) has identified MDPV or mephedrone in 461 exhibits of suspected controlled substances seized by law enforcement. 444 of these exhibits were found to contain MDPV and 17 were found to contain mephedrone.

CAS comment - what about MDPV alone?

3. ~~.....~~

s.21(1)(a)
s.21(1)(b)

Substances Act (CDSA).

As part of its scheduling assessment, Health Canada let an external contract aimed at assessing the abuse liability and dependence potential of MDPV. The assessment was completed in May 2012, and a comprehensive scheduling assessment is now underway with a target timeline of August 2012.

DGO comment - please provide some plain language examples on the assessment of abuse liability and dependence potential. Simply re-word what Tara sent earlier.

To initiate the regulatory process,

Timelines:

June 2012 - publication of *Notice to interested parties* in CGI

August 2012 - NOI comment period ends; submission of drafting instructions to HC drafting service

Fall 2012 - regulatory package preparation and approval

January/February 2013 - publication of regulation in CGII

4. We are planning to accelerate the scheduling of MDPV like we did for BZP (another designer recreational drug) through an NOI and CGII.

Based on the experience with BZP,

5. Please add in any other details you think would be useful.

Canadian media reports have originated primarily from Eastern provinces, including New Brunswick and Nova Scotia. On May 18, 2012, health officials in northern Nova Scotia issued a warning concerning the dangers posed by "bath salts", including reports of cases where use has resulted in the user requiring emergency care.

Andria Sherstone
DGO Advisor / Conseillère
Controlled Substances and Tobacco Directorate / Direction des substances contrôlées et de la lutte au tabagisme
Healthy Environments and Consumer Safety Branch / Direction générale de la santé environnementale et de la sécurité des consommateurs
Health Canada / Santé Canada
Tel: (613) 948-8951

s.21(1)(a)
s.21(1)(b)

Re: MO Request - Bath Salts 
Andria Sherstone to: Ian Hobler

2012-05-24 03:49 PM

Hi Ian,


Please see CSTD's response below:

1. A brief explanation of what bath salts are and what their ingredients are.

Over the past several months, there have been increasing media reports on synthetic stimulants sold under the guise of "bath salts" appearing in Canada. Law enforcement and border seizures of products labelled as "bath salts" have also been increasing. Such products are not genuine bath salt products, i.e., epsom salts, intended for softening/cleansing the skin, but contain one or more substances with stimulant properties such as mephedrone and methylone (which are already included in Schedule III to the CDSA as analogues of amphetamine), and 3,4-methylenedioxypyrovalerone (MDPV). MDPV, in particular, is most often sold as a powder and is reported to be administered through a wide range of modalities, with oral ingestion, injection, and nasal insufflation (snorting) being most prevalent. While the extent of their use in Canada is unknown, "bath salts" are available for purchase on the Internet and may be found in alternative lifestyle stores. Examples of product names include "MITSEEZ", "MOJO Novelty Bath Salts", "Ivory Snow", "Purple Wave", and "Vanilla Sky". These products may also be labelled as "plant food" and/or "not for human consumption" to circumvent regulatory control.

2. How seizure data has indicated that MDPV only bath salts are becoming more prevalent.

From January 2010 to present, Health Canada's Drug Analysis Service (DAS) has identified MDPV in 444 exhibits.

3. 

As part of its scheduling assessment, Health Canada let an external contract aimed at assessing the abuse liability and dependence potential of MDPV. The assessment was completed in May 2012, and concluded that based on MDPV's chemical structure, a similar abuse liability to amphetamine may be expected. In addition, because MDPV can be consumed in a number of different ways and has a short duration of action, it may be more appealing to drug users. With respect to physical dependence and tolerance, there is insufficient evidence on which to base any specific conclusions regarding MDPV at this point in time.

A comprehensive scheduling assessment is now underway with a target timeline of August 2012.

To initiate the regulatory process,

Timelines:

June 2012 - publication of *Notice to interested parties* in CGI

August 2012 - NOI comment period ends; submission of drafting instructions to HC drafting service

Fall 2012 - regulatory package preparation and approval

January/February 2013 - publication of regulation in CGII

4. We are planning to accelerate the scheduling of MDPV like we did for BZP (another designer recreational drug) through an NOI and CGII.

Based on the experience with BZP,

5. Please add in any other details you think would be useful.

Canadian media reports have originated primarily from Eastern provinces, including New Brunswick and Nova Scotia. On May 18, 2012, health officials in northern Nova Scotia issued a warning concerning the dangers posed by "bath salts", including reports of cases where use has resulted in the user requiring emergency care.

Andria Sherstone
DGO Advisor / Conseillère
Controlled Substances and Tobacco Directorate / Direction des substances contrôlées et de la lutte au tabagisme
Healthy Environments and Consumer Safety Branch / Direction générale de la santé environnementale et de la sécurité des consommateurs
Health Canada / Santé Canada
Tel: (613) 948-8951

Ian Hobler Hi Andria. MO has asked for an update on OCS... 2012-05-24 08:14:24 AM

From: Ian Hobler/HC-SC/GC/CA
To: "Andria Sherstone" <andria.sherstone@hc-sc.gc.ca>
Date: 2012-05-24 08:14 AM
Subject: MO Request - Bath Salts

Hi Andria.

MO has asked for an update on OCS's work on bath salts (MDPV specifically) for today.

Could I please get by mid-afternoon:

1. A brief explanation of what bath salts are and what their ingredients are.
2. How seizure data has indicated that MDPV only bath salts are becoming more prevalent.
3. HC has acted on the data by initiating work to schedule (break down the work in progress e.g. Triage questionnaire, pharmacology assessment, etc. and associated timelines)
4. We are planning to accelerate the scheduling of MDPV like we did for BZP (another designer recreational drug) through an NOI and CGII.
5. Please add in any other details you think would be useful.

I think we can avoid a fully-blown BN to MO if we get this up in time. Please note this is for MO's info on the policy side, not for communication to the public - media lines are still good for that.

Give me a call if you would like to discuss.

Thanks!
Ian



Fw: Note to file- Bath Salts
Andria Sherstone to: Cathy A Sabiston

2012-05-25 02:04 PM

FYI

Andria Sherstone
DGO Advisor / Conseillère
Controlled Substances and Tobacco Directorate / Direction des substances contrôlées et de la lutte au tabagisme
Healthy Environments and Consumer Safety Branch / Direction générale de la santé environnementale et de la sécurité des consommateurs
Health Canada / Santé Canada
Tel: (613) 948-8951

----- Forwarded by Andria Sherstone/HC-SC/GC/CA on 2012-05-25 02:03 PM -----

From: Johanne Beaulieu/HC-SC/GC/CA
To: "Sherstone, Andria" <andria.sherstone@hc-sc.gc.ca>
Date: 2012-05-25 01:09 PM
Subject: Fw: Note to file- Bath Salts

For your info.

Johanne
Jocelyn Kula

----- Original Message -----

From: Jocelyn Kula
Sent: 2012-05-25 12:21 PM EDT
To: Johanne Beaulieu
Subject: Fw: Note to file- Bath Salts

For your info per discussion yesterday. I am still completing the note from the other call with Nova Scotia Addiction Services.
Jocelyn

Jocelyn Kula
Manager, Regulatory Policy Division/ Gestionnaire, Division de la politique réglementaire
Office of Controlled Substances/ Bureau des substances contrôlées
Healthy Environments and Consumer Safety Branch/ Direction générale de la santé environnementale et de la sécurité des consommateurs
Health Canada/ Santé Canada
Tel: (613) 946-0125 Fax: (613) 946-4224
----- Forwarded by Ian McGillivray/HC-SC/GC/CA on 2012-05-25 12:19 PM -----

Note to file- Bath Salts

Jocelyn Kula to: Nathan Isotalo

2012-05-24 03:48 PM

Cc: Tara Phillips, Carol Anne Chénard

-returned a call to ██████████ which is a Halifax company that specializes in alternative smoke shop merchandise. ██████████ called Health Canada because he has received, over the past few weeks, several unsolicited samples of "bath salt" products from various American distributors that he normally does not deal with -the samples are small sachets of a white powder that looks like methamphetamine, and that are labelled "bath salts" or "glass cleaner" ██████████ noted his suspicions regarding the newer name "glass cleaner" as the latest attempt to avoid detection in the US where the name "bath salts" is widely associated with the recent scheduling of mephedrone, methylone and MDPV) -he and his staff have seen some of the media reports regarding bath salts and have also heard about some recent hospitalizations of young adults following the consumption of these products and wanted to make sure Health Canada was aware of the efforts of these distributors to get their products into stores in Canada. ██████████ then asked about disposal of the products and I referred him to the Health Canada Regional Office (who may want to investigate as an unapproved product under the Food and Drugs Act) and his local law enforcement detachment, and he indicated that he would send a sample to both ██████████ emphasized that he runs a very legitimate business and has always stayed away from drug like products such as salvia, datura, etc., and that he has no intention of stocking "bath salts", and thus, that he was contacting the department out of concern for the youth out there who may be exposed to them without knowing what they really are -I thanked ██████████ for having contacted the Department and indicated that we were certainly aware of these products and were presently establishing our next steps

Jocelyn

Jocelyn Kula
Manager, Regulatory Policy Division/ Gestionnaire, Division de la politique réglementaire
Office of Controlled Substances/ Bureau des substances contrôlées
Healthy Environments and Consumer Safety Branch/ Direction générale de la santé environnementale et
de la sécurité des consommateurs
Health Canada/ Santé Canada
Tel: (613) 946-0125 Fax: (613) 946-4224

s.21(1)(a)
s.21(1)(b)

Re: URGENT - Bath Salts

Andria Sherstone to: Johanne Beaulieu, Jocelyn Kula
Cc: "SoniaH Lindblad1", "Gisele Osta"

2012-05-30 12:40 PM

Also, wants to discuss an emergency walk about to get this scheduled faster.

Andria Sherstone Cathy would like to see you around the end of... 2012-05-30 12:37 PM EDT

From: Andria Sherstone
To: Johanne Beaulieu; Jocelyn Kula
Cc: SoniaH Lindblad1; Gisele Osta
Date: 2012-05-30 12:37 PM EDT
Subject: URGENT - Bath Salts

Cathy would like to see you around the end of the day to discuss the NOI.

Could you bring the latest version of the NOI please.



Fw: CBC Radio 1 (Toronto), The Current - The lethal new drug, Bath Salts -
30 May 2012, 8:40 AM

Andria Sherstone to: Johanne Beaulieu, Tara Phillips

2012-05-30 04:05 PM

FYI

HC_Media_SC

----- Original Message -----

From: HC_Media_SC
Sent: 2012-05-30 03:58 PM EDT
Subject: CBC Radio 1 (Toronto), The Current - The lethal new drug, Bath Salts - 30 May 2012, 8:40 AM

Distribution group/Groupe de distribution: Controlled Substances - Substances contrôlées - HECSB/DGSESC, DComm,

Station: CBC Radio 1 (Toronto)

DATE: Wed 30 May 2012

Program: The Current

Time: 8:40 AM

REPORTER: Anna Maria Tremonti

HEADLINE: The lethal new drug, Bath Salts

CBC (Anna Maria Tremonti; Host of The Current): Even by the sordid standard of drug crimes, the scene Miami Police broke up yesterday was beyond belief. Two naked men were found struggling on a busy downtown exit ramp. When a police officer got close enough to see what was happening, he was horrified and demanded the attacker stop. But the man just growled and continued the assault. Witnesses say the officer shot the man; the attack continued. Again and again, the officer fired. Only when the attacker was dead, did that assault stop. The victim was rushed to hospital gravely injured, his face almost completely eaten off. Authorities are not sure what would incite such a gruesome attack but they have a pretty good idea. They suspect a street drug named bath salts. It can cause delusions and wildly aggressive behaviour. And bath salts have made their way to this country. CBC National Reporter Stephen Puddicombe is following the story in northern Nova Scotia, where the use of this drug is causing alarm. And Stephen Puddicombe joins us from our Halifax studio. Good morning.

REPORTER (Stephen Puddicombe): Good morning Anna Maria.

CBC: Now, I've got to tell you, Stephen, this story from Florida is beyond frightening. Do bath salts typically cause behaviour like that?

REPORTER: Well, Anna Maria, this might be an extreme case but we are seeing more and more cases of violent and really bizarre behaviour from people high on these drugs, bath salts. I want to play you some sound from a video. It was shot by the Panama City Police in Florida. It's of a young man. He's handcuffed, he's in the back of a squad car and he's high on bath salts.

UNIDENTIFIED PERSON: What's your name?

UNIDENTIFIED PERSON 2: [laughter] [unintelligible; screaming]

REPORTER: There is a point, Anna Maria, where the young man goes quiet and I spoke to the police officer and he told me at that point he was sure if he wasn't handcuffed, he would have killed the officer or at least tried.

CBC: So what is this stuff made of to have such an impact, Stephen?

REPORTER: It's got several long names that I can't pronounce but it's comparable to part cocaine and part amphetamine and a whole bunch of minor drugs thrown in for good measure. For a more specific breakdown, I spoke to professor Louis De Felice at Virginia Commonwealth University School of Medicine. He's been studying bath salts.

LOUIS DE FELICE (Virginia Commonwealth University School of Medicine): The two main products of bath salts are called mephedrone and MDPV. Until recently, they were easily obtained, sold everywhere. The actual chemistry isn't that complicated, that's why I use the phrase kitchen chemistry. You can do very simple chemical steps that don't require a lot of instruments, don't require a lot of additional chemicals. No two bath salts are the same.

CBC: And the name bath salts, am I right in thinking it's because they look like the stuff you'd actually put in your bath?

REPORTER: You got it, Pontiac. But don't let that name fool you.

DE FELICE: It's as if you take--would take a very powerful amphetamine and a very powerful cocaine at the same time. This is not a recreational drug. So people that abuse this drug put themselves in a very dangerous and perhaps irreversible situation.

CBC: So we're talking about a serious street drug that puts users in a dangerous situation. It's not just a U.S. issue anymore, they're making their way to Canada. Do we know how pervasive they are in this country at this point?

REPORTER: You know, it's really hard to say. They have turned up in small pockets in Ontario, New Brunswick, Winnipeg. And here in Nova Scotia, it's starting to grow. And health officials are really concerned that this drug may spread. And after learning more about bath salts and seeing it's toll up close, I can see why.

CBC: Well, you spoke to a bath salt user in Nova Scotia, huh? Tell us about it.

REPORTER: Well, we met at the detox unit in New Glasgow in northern Nova Scotia. We sat down. It was a nondescript room, the sun coming through the windows. He's in his forties, looks much older than that. He's tall, thin, balding, little wisp of facial hair. Very well spoken. But his demeanor changed when we talked about bath salts. He spoke to us on the condition that we wouldn't use his real name, so we'll call him John.

JOHN (Bath Salt User): I started using bath salts on a daily functioning of my life, would have been mid-February. The very first time was probably December last year. A fellow was over and he said, I got this new stuff, let's try this new stuff. So I said yeah, okay, 'cause well, can't have an opinion on something you don't experiment with. So experiment I did. Eight days straight, with no sleep. That's when you come to realize the drug's got you.

CBC: Eight days no sleep?

REPORTER: Hard to believe, right? So but John says the first time he really got into it was in February and well, it scared the living daylights out of him. And he says--this is a long time addict, he's a veteran of many other drugs--and John says bath salts make you violent or at least it puts violent thoughts in your head.

JOHN: On that eight day stretch, I come down and I had my issues on a psychotic level.

REPORTER: Like what?

JOHN: Like where I felt like I wanted to kill me or I wanted to kill somebody else. Horrible feeling of sketchiness, constantly looking over your shoulder or peeking out around your curtain windows, hiding

under the blankets kind of thing. I went in the hospital for--at the end of my eight day stretch, I was in for a day and a half. I come out of the hospital, I went home and I never moved outside of my house for another week.

REPORTER: You know, as I said, Anna Maria, extreme violence is one of the key effects of this drug and it's scaring the daylights as well out of doctors and addiction workers. Doctor Heidi Farinholt is a physician from the States. She's now working here in Nova Scotia in New Glasgow. She's a young doctor, a bit of a stern look when I talked to her. I talked to her just outside the emergency ward in a hallway of the Aberdeen Hospital in New Glasgow. She says the problem is the drug is so new, that most in the medical field didn't really know what to do about it or how to treat people who overdose.

DOCTOR HEIDI FARINHOLT (Aberdeen Hospital): I've seen this down in the United States. We had a big problem with it down, especially in the rural areas of the United States. About a year and a half ago is when we started to see it. At the time, I was working at the Eastern Maine Medical Centre in Bangor. And that was really one of the hot spots for it. So we knew this was this new drug. As we found out more and more about it though and we saw more and more patients, we realized that this is something that was extremely dangerous. And as we saw increasing usage, the more people you see with it, the more likely you are to see somebody with a severe reaction. And that's what we started to see. So a lot of it, nobody knew about it, you know. So we had to take a lot of what we were seeing and kind of shoestring together ways to take care of these patients.

CBC: Doctor Farinholt mentions it being a rural problem in the States. Is it mostly a rural issue here too?

REPORTER: Yeah, so far it seems to be but as I said, health officials worry that it could spread.

CBC: And it's pretty addictive, huh?

REPORTER: Oh yeah. Doctor Farinholt says she's seen nothing in the drug world like bath salts.

FARINHOLT: Extremely addictive, actually. It's one of the, probably one of the most addictive substances out there because it's a very rapid onset, very wild, crazy, euphoria but then also has a very rapid decline from that euphoria. And because of that, you know, you have it once and you want more and more and more of it. So very difficult to get people off of it. It seems to be more so than many other drugs that we've seen.

REPORTER: And Anna Maria, doctors like Doctor Farinholt aren't the only ones seeing this. Greg Purvis is the director of addictions counseling in Pictou County, the part of Nova Scotia really struggling with bath salts right now. He says this problem is bad and it's growing.

GREG PURVIS (Director of Addictions Counseling): We're seeing negative side effects of this drug quicker than we've seen with any other drug that's hit the streets. So folks are ended up in the emergency rooms with hallucinations, delusions, psychosis--very bizarre behaviour. A lot of combativeness, a lot of agitation, a lot of aggression. Very high propensity for violence with this drug, yes. We're having about one to three clients a week in our detox unit here in Pictou. The emergency room, the Aberdeen, has seen several cases and a couple weeks ago, we heard that the emergency room in Colchester-East Hants was starting to see cases.

REPORTER: Now that's the addiction counselor's perspective on how bad it is. Here's the addict's perspective.

JOHN: It can be pretty harsh at times, for some of the thoughts and some of the feelings. And the most I really got, were the shadows. I'd catch a shadow go by a door or something and it could have been a tree blowing in the wind, it could have been a ball bouncing across the floor or whatever. Hearing people talk to me, but that's most I've experienced with any of that. With this drug, I just wanted to keep going.

CBC: Okay, so that's John, the addict from New Glasgow. He wanted to keep going, even after extremely

creepy, almost haunting effects? Stephen, what are some of the other physical side effects of bath salts?

REPORTER: Jeez, you know, we could spend an hour on them. They run the gambit. And here's Doctor Heidi Farinholt and addictions counselor Greg Purvis again, to explain.

FARINHOLT: We've seen fatalities from it. A lot of patients that have used this end up having, you know, tachycardia, you know, an increased heart rate, an increase in blood pressure, we've seen some with kidney failure, there are some that, you know, become hypothermic, very overheated, going into almost like a heat stroke type pattern. And then we have seen a number of cases of cardiac arrest down in the United States. We haven't seen any here in New Glasgow as of yet but that's, you know, unfortunately the operative word for that might be just yet.

PURVIS: I've been working in addictions for nineteen years and I've gone through the methamphetamine scare, the crack cocaine scare. This is the first one that really has me concerned. I've never been an alarmist and I'm not a prohibitionist when it comes to drugs and alcohol--I respect people's ability to make choices, our job is really to help them with those choices when it starts to adversely affect them. We think this drug is a very harmful choice for a lot of folks.

CBC: Wow. Okay, so Stephen, John, the man dealing with his addiction to bath salts, the man with whom you spoke, ended up in intensive care after eight days on the drug. How is he now?

REPORTER: It's interesting because during part of our interview, he started talking or taking a different tone about bath salts, almost like he was trying to convince me, well, you know, really they're not that bad despite his earlier references to wanting to kill himself or kill somebody else. But after his hospital stay, he went into detox.

JOHN: I come into detox and I was scared of the drug because I seen what it done to me. And the day I came into detox, I had a slip the night before. It was after a couple of days, I guess. I started calming down. My agitations--well, my agitations were still there, just not as bad. The fact that I realize now, once again, I'm addicted to something else, I was to a point that I knew I needed help because if not, I would lose my job and everything else that went along with it. And if I continued on, I probably may have considered suicide on a stronger level. I was scared, I was nervous, I was anxious. I just couldn't face a lot of things anymore and it was a drug that definitely left a scar upon me. It is the first drug that I never really could control. Would I be here today? Probably not.

CBC: The first one he couldn't control. Now, we keep hearing over and over then, how dangerous these bath salts are and yet they're apparently easy to come by?

REPORTER: You can legally buy them on the internet. A couple of clicks, credit card and wham, you have bath salts. But in rural Nova Scotia, I'm hearing that people are actually getting them directly from the drug dealers. Here is Doctor Farinholt again on how accessible bath salts are.

FARINHOLT: They are currently not difficult to get at all and that's part of the problem with them. What we saw in Bangor, when these things first came out, was that they were so easy to get, that the people who were pushing OxyContin and Percocet and Dilaudid on the street, had to drop their prices and were a little bit torqued that they were losing their market because this was so easy to get.

CBC: Easy to get but in some places, Stephen, illegal.

REPORTER: Ah and this is the heart of the story, I think. The United States moved quickly last fall after several bath salts related deaths. The Drug Enforcement Administration used its powers to put an emergency ban on the drugs--it rarely does that--that make up bath salts. Rusty Payne speaks for the DEA based in Washington D.C. I spoke to him on the phone.

RUSTY PAYNE (Drug Enforcement Administration): We believe that these products do present an imminent threat that has been borne out by the number of emergency room mentions and other problems

at state and local law enforcement have reported. They're in the thousands, between synthetic cannabinoids--or synthetic pot--and synthetic stimulants, which is the mephedrone or the MDPV, which is known as bath salts. These synthetic chemicals are just causing so many problems across the country and now obviously into Canada and other parts of the world.

REPORTER: Anna Maria, that ban on bath salts in the United States is temporary and expires in October but the federal Department of Health will look at it and determine if a permanent ban is needed. Congress also has a bill in the works that if passed, also bans bath salts. Now, elsewhere in the world, bath salts have already been banned in Australia, some countries in Europe, the UK. But part of the problem with banning these types of drugs is street chemists are so smart, they can change their brew to skirt most bans. Greg Purvis, the addictions counselor you heard from earlier from Pictou County, Nova Scotia, says Australia has put into place legislation that deals with that problem.

PURVIS: When I look at the legislation that is behind this in the different countries, Australia has this amazing legislation that looks at if a drug is banned, any chemical derivative of that drug is automatically banned once it's produced. So Australia doesn't have to play catch up with street chemists. So once methamphetamine comes out, any drug that's close to methamphetamine is automatically banned. And I don't believe we have that in Canada and I'm pretty sure they didn't have that in the States. So now, every time a new derivative of a drug comes out, it has to go through this whole process again. It would be great through working through this, if we could put legislation like that in Canada.

CBC: So what about here in Canada, Stephen? What is the government doing about this problem?

REPORTER: Well, I requested an interview with Health Canada but was turned down. Instead, they emailed me a statement. And in a nutshell, it says Health Canada is looking at bath salts and working with law enforcement agencies to determine the most appropriate next steps to address the public health and safety risks associated with their use. The statement adds that Health Canada does not recommend the use of these products because of their potentially dangerous health effects and also because little is known about their potential long term effects on the brain and body. I'm just reading straight from what the email they sent me. Doctor Heidi Farinholt says that given what she knows about bath salts, she says that answer from Health Canada isn't good enough.

FARINHOLT: I think they should take a very close look at this drug. This is one of the most lethal, I think, illegal drugs that we have out there. One of it is because the information is not out yet and the other thing is just the nature of the way the drug works. It's very closely related to both cocaine and other stimulants and because of that, it is extremely dangerous. So you basically take cocaine, you multiply it by about a factor of ten and you have this. My training was done down in Baltimore, Maryland, which is one of the roughest places to work in the United States. Saw a lot of drugs, a lot of guns. And I have to say, this drug scares me more than any of that ever did because of just the risk, the, you know, the difficulty in treating these patients. Some of them have, you know, paranoid, mental symptoms and such, you know, well--months down the road. So you have the difficulty of that already stressing your mental health system but then also the risk of, you know, death. We've had patients--not here--but patients down in the United States that committed suicide. It's a very malignant drug and one that I hope we get off the streets as quickly as possible.

REPORTER: And just to add to that, Anna Maria, there is one thing that they all say--the police, the addiction counselors, the doctors--they're united in their goal, which is very rare when it comes to anything in the drug world. I'll give the final word about bath salts today to John, the recovering addict I spoke to from New Glasgow.

JOHN: I come close to losing me. I was into a pretty much drug induced coma. My pulse rate, from what I was told, was next to nonexistent. My body was limp and lifeless. The person that actually walked into the room told me that he thought I was almost dead.

CBC: That's really powerful stuff, Stephen. I have to ask you though, you know, I mean, you're reporting on this out of Nova Scotia. Doctor Farinholt is talking about her experience and talking about

Bangor--Bangor, Maine, which is just over the border from the Maritimes. Does it seem to be concentrated there because it's coming up from the east coast of the U.S.?

REPORTER: That's a good question. The only thing they can really get is that the bottom line with this drug is that it's not that expensive, it's easy to get on the internet and most other drugs are more difficult to get in smaller areas and rural areas and small towns. And they just figured it must have made its way somehow just like the route you said--from Bangor up through a pocket of New Brunswick because it did hit Rothesay last September, where they made a seizure and now it's been in Amherst, it's all across the northern part of Nova Scotia, which is along the Trans-Canada Highway, essentially, in small town Nova Scotia.

CBC: Huh. Well, really disturbing. Thanks for bringing us this story.

REPORTER: My pleasure, Anna Maria.

CBC: That is Stephen Puddicombe. He is the National Reporter for CBC Radio in the Maritimes and he was in our Halifax studio.

You are receiving this e-mail because you are subscribed to the distribution group identified at the top of this e-mail message. If you wish to unsubscribe from this group, please reply to this message or send a request to HC_Media_SC@hc-sc.gc.ca

Thank you.

Media Monitoring Team
HC/SC - PHAC/ASPC

Vous recevez ce courriel parce que vous faites partie du groupe de distribution qui apparaît en haut du présent courriel. Si vous désirez que votre nom soit retiré de ce groupe, veuillez répondre à ce courriel et demander que votre nom soit retiré ou envoyer une demande à HC_Media_SC@hc-sc.gc.ca
Merci.

L'Équipe de surveillance des médias
HC/SC - PHAC/ASPC

Check out Newslink: Media Monitoring's new and improved web presence
Consultez Newslink: nouveau site amélioré de la Surveillance des médias

Re: Fw: For Approval: Updated QP Note on MDPV in Bath Salts

Andria Sherstone to: Johanne Beaulieu

2012-05-30 05:09 PM

Cc: CSTD-OCS-DO, "Kula, Jocelyn", "Phillips, Tara"

DG approved with edits. Note that the second key message was changed to align with the media lines.



Andria Sherstone
DGO Advisor / Conseillère
Controlled Substances and Tobacco Directorate / Direction des substances contrôlées et de la lutte au tabagisme
Healthy Environments and Consumer Safety Branch / Direction générale de la santé environnementale et de la sécurité des consommateurs
Health Canada / Santé Canada
Tel: (613) 948-8951

Johanne Beaulieu Approved. ----- Original Message -----

2012-05-30 01:31:03 PM

From: Johanne Beaulieu/HC-SC/GC/CA
To: "Sherstone, Andria" <andria.sherstone@hc-sc.gc.ca>
Cc: "Phillips, Tara" <tara.phillips@hc-sc.gc.ca>, "Kula, Jocelyn" <jocelyn.kula@hc-sc.gc.ca>,
CSTD-OCS-DO
Date: 2012-05-30 01:31 PM
Subject: Fw: For Approval: Updated QP Note on MDPV in Bath Salts

Approved.

Tara Phillips

----- Original Message -----

From: Tara Phillips
Sent: 2012-05-30 11:04 AM EDT
To: Johanne Beaulieu
Cc: Jocelyn Kula; CSTD-OCS-DO
Subject: For Approval: Updated QP Note on MDPV in Bath Salts

Hi Johanne,

Attached is the link to the revised QP Note on MDPV in Bath Salts, for your approval.



Comms is still working on the Media Lines.

Thank you,

Tara
946-6521

**QUESTION PERIOD NOTE
NOTE POUR LA PÉRIODE DE
QUESTIONS**

Date:	May 30, 2012
Classification :	HECS PROTECTED - SESC PROTÉGÉ

English:

MDPV IN BATH SALTS

SYNOPSIS - SOMMAIRE

English:

Health officials in northern Nova Scotia have issued a warning concerning the dangers posed by an emerging street drug known as "bath salts". On May 30, 2012, there was a feature story on the use of "bath salts" on CBC Radio's The Current, adding to the growing body of media reports. "Bath salts" may contain one or more substances with stimulant properties such as MDPV (3,4-methylenedioxypyrovalerone), mephedrone and/or methylone. Such products are likely labelled as "bath salts" in order to appear legal. Both methylone and mephedrone are considered controlled substances in Canada, while MDPV is not yet included in one of the Schedules to the Controlled Drugs and Substances Act (CDSA). Canadian law enforcement and border services are seeing an increasing trend in the incidence of "bath salts" seizures later found to contain MDPV.

ANTICIPATED QUESTION - QUESTION PRÉVUE

English:

What is the Government doing about MDPV in bath salts?

English:

- This Government is very concerned about the public health and safety risks associated with the use of "bath salts". ~~the recent drug analyses and seizures of so-called "bath salts"~~ containing a substance called MDPV.
- Health Canada is assessing MDPV, a key ingredient in "bath salts", for scheduling under the *Controlled Drugs and Substances Act*. ~~Health Canada will be working with law enforcement agencies to determine the most appropriate next steps to address the public health and safety risks associated with the use of MDPV.~~
- This Government is committed to controlling substances that produce harm to health and to society when abused.

Français:

BACKGROUND - CONTEXTE

English:

A number of recent media articles in both the United States and Canada have highlighted dangers posed by products labelled and marketed as "bath salts" which are being used as amphetamine-like stimulants. These products are not genuine bath salt products at all, which are typically composed of water soluble mineral salts and are added to water for the purpose of cleansing, softening and/or perfuming the skin.

Canadian media reports have originated primarily from Eastern provinces, including New Brunswick and Nova Scotia. On May 18, 2012, health officials in northern Nova Scotia issued a warning concerning the dangers posed by "bath salts", including reports of cases where use has resulted in the user requiring emergency care.

Preliminary reports indicate that the psychoactive ingredients contained in "bath salts" products may include mephedrone, methylone and/or MDPV (3,4-methylenedioxypyrovalerone). In addition, there have been reports of "bath salts" being used to lace other drugs such as marihuana.

Mephedrone and methylone are analogues of amphetamine and is thus considered to be included in Item 1 of

Schedule III to the CDSA. ~~Adverse effects associated with the use of amphetamines can include seizures, cerebral hemorrhage, high fever, coma or death.~~

MDPV is a central nervous system stimulant. Adverse physical effects associated with the use of stimulants can include palpitations, irregular or abnormal heartbeat, heart attack or cardiovascular collapse. MDPV use has also been associated with severe panic attacks and anxiety, as well as hallucinations and psychosis. ~~whose use can cause increased blood pressure and increased heart rate. The use of MDPV has also been associated with panic attacks, anxiety and, hallucinations, suicidal thoughts, tendencies and death.~~ MDPV is not regulated as a controlled substance in Canada.

~~From other analyses~~, from January 2010 to present, Health Canada's Drug Analysis Service (DAS) has identified MDPV or mephedrone in 461332 exhibits of suspected controlled substances seized by law enforcement. 444315 of these exhibits were found to contain MDPV alone. Only 17 were found to contain mephedrone.

The CDSA prohibits all activities, e.g., possession, production, distribution, sale, import, and/or export, involving substances listed in one of the Schedules to the Act, unless authorized by regulation. Health Canada considers several factors in determining whether the scheduling of a substance under the Controlled Drugs and Substances Act (CDSA) is warranted. These include:

- Overall risk to public health and safety posed by the substance;
- Chemical and pharmacological similarity to other substances already regulated under the CDSA;
- Legitimate uses of the substance (i.e., therapeutic, industrial or commercial);
- Potential for abuse and risk of addiction associated with the substance;
- Extent of actual abuse of the substance in Canada and internationally; and
- International requirements and trends in international control.

In the United States, the Drug Enforcement Administration ~~has recently used its emergency scheduling authority to temporarily ban mephedrone, MDPV and methylone in September 2011. MDPV has also recently been banned in the United Kingdom.~~

No drug products containing MDPV or mephedrone have been approved for sale in Canada.

~~Health Canada will continue to work with law enforcement agencies in determining the most appropriate next steps in addressing the public health and safety risks associated with the use of MDPV.~~

ATTACHMENTS / PIÈCE(S)-JOINTE(S)			

Contact/Personne ressource : Jocelyn Kula/HC-SC/GC/CA	Tel. no./No de tél. 946-0125	Approved by/ Approuvé par Hilary Geller, ADM (HECS/SESC)	Tel. no./No. de tél. 946-6701
	Mobile/ Cellulaire:	Title/ Titre:	Mobile/ Cellulaire:
Alternate/ Secondaire: Tara Phillips	Telephone/ Téléphone: 946-6521		
	Mobile/ Cellulaire:		

Date Prepared/Préparé le : 2012-05-23

Prepared by/Préparé par : Nathan Isotalo **Phone/ No de tél. :** 613-941-1511

Office/Bureau : CSTD - Office of Controlled Substances

**Date Contact Signed/
Signature de la personne
ressource :** 2012-05-30 **Contact Signed - Signé**

**D.G. Verification/
Vérification par le D.E. :** Cathy Sabiston **D.G. Approved / Approuvé D.E.**

**Date D.G. Verified/
Date vérifié par le D.E. :** 2012-05-30

Programme : Controlled Substances and Tobacco Directorate

**ADM Approved/ Approbation
par le SMA :** Hilary Geller, ADM (HECS/SESC)
(946-6701)

Branch/ Direction générale : HECS/SESC

Department/ Ministère : Health Canada / Santé Canada



QP for Bath Salts

Andria Sherstone to: Johanne Beaulieu
Cc: CSTD-OCS-DO, Tara Phillips, Jocelyn Kula

2012-05-30 05:44 PM

We were advised that the language on HC activities should in fact be softer. As such, I reverted to your original lines on assessing it for scheduling.



Andria Sherstone
DGO Advisor / Conseillère
Controlled Substances and Tobacco Directorate / Direction des substances contrôlées et de la lutte au tabagisme
Healthy Environments and Consumer Safety Branch / Direction générale de la santé environnementale et de la sécurité des consommateurs
Health Canada / Santé Canada
Tel: (613) 948-8951

QUESTION PERIOD NOTE NOTE POUR LA PÉRIODE DE QUESTIONS

Date:	May 30, 2012
Classification	HECS PROTECTED - SESC PROTÉGÉ

English:

MDPV IN BATH SALTS

SYNOPSIS - SOMMAIRE

English:

Health officials in northern Nova Scotia have issued a warning concerning the dangers posed by an emerging street drug known as "bath salts". On May 30, 2012, there was a feature story on the use of "bath salts" on CBC Radio's The Current, adding to the growing body of media reports. "Bath salts" may contain one or more substances with stimulant properties such as MDPV (3,4-methylenedioxypyrovalerone), mephedrone and/or methylone. Such products are likely labelled as "bath salts" in order to appear legal. Both methylone and mephedrone are considered controlled substances in Canada, while MDPV is not yet included in one of the Schedules to the Controlled Drugs and Substances Act (CDSA). Canadian law enforcement and border services are seeing an increasing trend in the incidence of "bath salts" seizures later found to contain MDPV.

ANTICIPATED QUESTION - QUESTION PRÉVUE

English:

What is the Government doing about MDPV in bath salts?

English:

- This Government is very concerned about the public health and safety risks associated with the use of "bath salts". ~~the recent drug analyses and seizures of so-called "bath salts" containing a substance called MDPV.~~
- Health Canada is assessing MDPV, a key ingredient in "bath salts", for scheduling under the *Controlled Drugs and Substances Act*. ~~Health Canada will be working with law enforcement agencies to determine the most appropriate next steps to address the public health and safety risks associated with the use of MDPV.~~
- This Government is committed to controlling substances that produce harm to health and to society when abused.

Français:

BACKGROUND - CONTEXTE

English:

A number of recent media articles in both the United States and Canada have highlighted dangers posed by products labelled and marketed as "bath salts" which are being used as amphetamine-like stimulants. These products are not genuine bath salt products at all, which are typically composed of water soluble mineral salts and are added to water for the purpose of cleansing, softening and/or perfuming the skin.

Canadian media reports have originated primarily from Eastern provinces, including New Brunswick and Nova Scotia. On May 18, 2012, health officials in northern Nova Scotia issued a warning concerning the dangers posed by "bath salts", including reports of cases where use has resulted in the user requiring emergency care.

Preliminary reports indicate that the psychoactive ingredients contained in "bath salts" products may include mephedrone, methylone and/or MDPV (3,4-methylenedioxypyrovalerone). In addition, there have been reports of "bath salts" being used to lace other drugs such as marihuana.

Mephedrone and methylone are analogues of amphetamine and is thus considered to be included in Item 1 of

Schedule III to the CDSA. ~~Adverse effects associated with the use of amphetamines can include seizures, cerebral hemorrhage, high fever, coma or death.~~

MDPV is a central nervous system stimulant. Adverse physical effects associated with the use of stimulants can include palpitations, irregular or abnormal heartbeat, heart attack or cardiovascular collapse. MDPV use has also been associated with severe panic attacks and anxiety, as well as hallucinations and psychosis. ~~whose use can cause increased blood pressure and increased heart rate. The use of MDPV has also been associated with panic attacks, anxiety and hallucinations, suicidal thoughts, tendencies and death.~~ MDPV is not regulated as a controlled substance in Canada.

~~From other analyses, from January 2010 to present, Health Canada's Drug Analysis Service (DAS) has identified MDPV or mephedrone in 461332 exhibits of suspected controlled substances seized by law enforcement. 444315 of these exhibits were found to contain MDPV alone. Only 18 and the other 17 were found to contain mephedrone.~~

The CDSA prohibits all activities, e.g., possession, production, distribution, sale, import, and/or export, involving substances listed in one of the Schedules to the Act, unless authorized by regulation. Health Canada considers several factors in determining whether the scheduling of a substance under the Controlled Drugs and Substances Act (CDSA) is warranted. These include:

- Overall risk to public health and safety posed by the substance;
- Chemical and pharmacological similarity to other substances already regulated under the CDSA;
- Legitimate uses of the substance (i.e., therapeutic, industrial or commercial);
- Potential for abuse and risk of addiction associated with the substance;
- Extent of actual abuse of the substance in Canada and internationally; and
- International requirements and trends in international control.

~~In the United States, the Drug Enforcement Administration has recently used its emergency scheduling authority to temporarily ban mephedrone, MDPV and methylone in September 2011. MDPV has also recently been banned in the United Kingdom.~~

No drug products containing MDPV or mephedrone have been approved for sale in Canada.

~~Health Canada will continue to work with law enforcement agencies in determining the most appropriate next steps in addressing the public health and safety risks associated with the use of MDPV.~~

ATTACHMENTS / PIÈCE(S)-JOINTE(S)			

Contact/Personne ressource : Jocelyn Kula/HC-SC/GC/CA	Tel. no./No de tél. 946-0125	Approved by/ Approuvé par Hilary Geller, ADM (HECS/SESC)	Tel. no./No. de tél. 946-6701
	Mobile/ Cellulaire:	Title/ Titre:	Mobile/ Cellulaire:
Alternate/ Secondaire: Tara Phillips	Telephone/ Téléphone: 946-6521		
	Mobile/ Cellulaire:		

Date Prepared/Préparé le : 2012-05-23

Prepared by/Préparé par : Nathan Isotalo **Phone/ No de tél. :** 613-941-1511

Office/Bureau : CSTD - Office of Controlled Substances

**Date Contact Signed/
Signature de la personne
ressource :** 2012-05-30 **Contact Signed - Signé**

**D.G. Verification/
Vérification par le D.E. :** Cathy Sabiston **D.G. Approved / Approuvé D.E.**

**Date D.G. Verified/
Date vérifié par le D.E. :** 2012-05-30

Programme : Controlled Substances and Tobacco Directorate

**ADM Approved/ Approbation
par le SMA :** Hilary Geller, ADM (HECS/SESC)
(946-6701)

Branch/ Direction générale : HECS/SESC

Department/ Ministère : Health Canada / Santé Canada

s.21(1)(a)

s.21(1)(b)

Re: URGENT - Bath Salts Q from MO

Andria Sherstone to: Johanne Beaulieu

Cc: Jocelyn Kula, Tara Phillips

2012-05-31 11:10 AM

Just spoke with Jocelyn and she provided some further clarification as to our activities.

Johanne, do you approve the lines below?

Andria Sherstone
DGO Advisor / Conseillère
Controlled Substances and Tobacco Directorate / Direction des substances contrôlées et de la lutte au tabagisme
Healthy Environments and Consumer Safety Branch / Direction générale de la santé environnementale et de la sécurité des consommateurs
Health Canada / Santé Canada
Tel: (613) 948-8951

Johanne Beaulieu Super Approved

2012-05-31 11:04:06 AM

From: Johanne Beaulieu/HC-SC/GC/CA
To: Andria Sherstone/HC-SC/GC/CA@HWC
Cc: Jocelyn Kula/HC-SC/GC/CA@HWC, Tara Phillips/HC-SC/GC/CA@HWC
Date: 2012-05-31 11:04 AM
Subject: Re: URGENT - Bath Salts Q from MO

Super. Approved.

Andria Sherstone How about: Health Canada continues to collab...

2012-05-31 11:00 AM EDT

From: Andria Sherstone
To: Johanne Beaulieu
Cc: Jocelyn Kula; Tara Phillips
Date: 2012-05-31 11:00 AM EDT
Subject: Re: URGENT - Bath Salts Q from MO

How about:

Andria Sherstone

000065

DGO Advisor / Conseillère
Controlled Substances and Tobacco Directorate / Direction des substances contrôlées et de la lutte au tabagisme
Healthy Environments and Consumer Safety Branch / Direction générale de la santé environnementale et de la sécurité des consommateurs
Health Canada / Santé Canada
Tel: (613) 948-8951

Johanne Beaulieu Would you not want to talk about who we talked... 2012-05-31 10:58:46 AM

From: Johanne Beaulieu/HC-SC/GC/CA
To: Andria Sherstone/HC-SC/GC/CA@HWC, Jocelyn Kula/HC-SC/GC/CA@HWC
Cc: Tara Phillips/HC-SC/GC/CA@HWC
Date: 2012-05-31 10:58 AM
Subject: Re: URGENT - Bath Salts Q from MO

Would you not want to talk about who we talked to?

--

Johanne

Andria Sherstone O-k, so are you comfortable with the statemen... 2012-05-31 10:52 AM EDT

From: Andria Sherstone
To: Jocelyn Kula
Cc: Johanne Beaulieu; Tara Phillips
Date: 2012-05-31 10:52 AM EDT
Subject: Re: URGENT - Bath Salts Q from MO

O-k, so are you comfortable with the statement below (MO wants two sentences):

Andria Sherstone
DGO Advisor / Conseillère
Controlled Substances and Tobacco Directorate / Direction des substances contrôlées et de la lutte au tabagisme
Healthy Environments and Consumer Safety Branch / Direction générale de la santé environnementale et de la sécurité des consommateurs
Health Canada / Santé Canada
Tel: (613) 948-8951

Jocelyn Kula To be clear, we have not had formal consultation... 2012-05-31 10:33:11 AM

From: Jocelyn Kula/HC-SC/GC/CA
To: Andria Sherstone/HC-SC/GC/CA@HWC
Cc: CSTD-OCS-DO, Johanne Beaulieu/HC-SC/GC/CA@HWC, Tara Phillips/HC-SC/GC/CA@HWC
Date: 2012-05-31 10:33 AM
Subject: Re: URGENT - Bath Salts Q from MO

To be clear, [REDACTED] We have however been in communication with these departments in the following way:

-exchange of emails and telephone conversations [REDACTED]

-at the last SDI Working Group, we mentioned that we had initiated work on a scheduling assessment and that we were planning to do an NOI but did not have specific timelines for publication

-as we know that [REDACTED]

Let me know if you need anything further
Jocelyn

Jocelyn Kula
Manager, Regulatory Policy Division/ Gestionnaire, Division de la politique réglementaire
Office of Controlled Substances/ Bureau des substances contrôlées
Healthy Environments and Consumer Safety Branch/ Direction générale de la santé environnementale et de la sécurité des consommateurs
Health Canada/ Santé Canada
Tel: (613) 946-0125 Fax: (613) 946-4224

Andria Sherstone MO would like an update on the recent contact... 2012-05-31 10:13:06 AM

From: Andria Sherstone/HC-SC/GC/CA
To: Johanne Beaulieu/HC-SC/GC/CA@HWC
Cc: Jocelyn Kula/HC-SC/GC/CA@HWC, Tara Phillips/HC-SC/GC/CA@HWC, Denis Arsenault/HC-SC/GC/CA@HWC, CSTD-OCS-DO
Date: 2012-05-31 10:13 AM
Subject: URGENT - Bath Salts Q from MO

MO would like an update on the recent contact HC has had with law enforcement with respect to bath salts. Could you provide me with an update on how our work with law enforcement has been progressing since we started the scheduling assessment? [REDACTED] Have we simply been engaging in more information sharing?

ASAP please.

Thanks!
-A

Andria Sherstone
DGO Advisor / Conseillère

Controlled Substances and Tobacco Directorate / Direction des substances contrôlées et de la lutte au
tabagisme
Healthy Environments and Consumer Safety Branch / Direction générale de la santé environnementale et
de la sécurité des consommateurs
Health Canada / Santé Canada
Tel: (613) 948-8951



Fw: Information on Bath Salts

Andria Sherstone to: Johanne Beaulieu, Jocelyn Kula, Tara Phillips

2012-05-31 12:07 PM

FYI - this is what went up to MO on Bath Salts this week (we had provided input late last week)

Andria Sherstone
DGO Advisor / Conseillère
Controlled Substances and Tobacco Directorate / Direction des substances contrôlées et de la lutte au tabagisme
Healthy Environments and Consumer Safety Branch / Direction générale de la santé environnementale et de la sécurité des consommateurs
Health Canada / Santé Canada
Tel: (613) 948-8951

----- Forwarded by Andria Sherstone/HC-SC/GC/CA on 2012-05-31 12:05 PM -----

From: Ian Hobler/HC-SC/GC/CA
To: "Andria Sherstone" <andria.sherstone@hc-sc.gc.ca>
Date: 2012-05-31 10:09 AM
Subject: Fw: Information on Bath Salts

Ian Hobler

----- Original Message -----

From: Ian Hobler
Sent: 2012-05-29 04:44 PM EDT
To: Steven Schwendt
Subject: Fw: Information on Bath Salts

Hi Steve.

Here is the info on bath salts that went to George in MO from Linsey.

ADM approved.

Ian

----- Forwarded by Ian Hobler/HC-SC/GC/CA on 2012-05-29 04:43 PM -----

From: Ian Hobler/HC-SC/GC/CA
To: Linsey Hollett/HC-SC/GC/CA@HWC
Date: 2012-05-29 03:37 PM
Subject: Information on Bath Salts



Bath Salts Info for MO.doc

Info on Bath Salts for the Minister's Office – for approval

Over the past several months, there have been increasing media reports on synthetic stimulants sold under the guise of "bath salts" appearing in Canada. Law enforcement and border seizures of products labelled as "bath salts" have also been increasing. Such products are not genuine bath salt products, i.e., epsom salts, intended for softening/cleansing the skin, but contain one or more substances with stimulant properties such as mephedrone and methylone (which are already included in Schedule III to the *Controlled Drugs and Substances Act* (CDSA) as analogues of amphetamine), and 3,4-methylenedioxypyrovalerone (MDPV – which is not included in a schedule to the CDSA). MDPV, in particular, is most often sold as a powder and is reported to be administered through a wide range of modalities, with oral ingestion, injection, and nasal insufflation (snorting) being most prevalent. While the extent of their use in Canada is unknown, "bath salts" are available for purchase on the Internet and may be found in alternative lifestyle stores. Examples of product names include "MITSEEZ", "MOJO Novelty Bath Salts", "Ivory Snow", "Purple Wave", and "Vanilla Sky". These products may also be labelled as "plant food" and/or "not for human consumption" to circumvent regulatory control.

From January 2010 to present, Health Canada's Drug Analysis Service (DAS) has identified MDPV in 444 exhibits.

Canadian media reports have originated primarily from Eastern provinces, including New Brunswick and Nova Scotia. On May 18, 2012, health officials in northern Nova Scotia issued a warning concerning the dangers posed by "bath salts", including reports of cases where use has resulted in the user requiring emergency care.

Health Canada is taking steps to add MDPV to a schedule to the CDSA, rendering it illegal.

As part the assessment to add MDPV to a schedule to the CDSA, Health Canada has assessed the abuse liability and dependence potential of MDPV. The assessment, completed in May 2012, concluded that based on MDPV's chemical structure, one can expect a similar abuse liability to amphetamine. In addition, because MDPV can be consumed in a number of different ways and has a short duration of action, it may be more appealing to drug users. With respect to physical dependence and tolerance, there is insufficient evidence on which to base any specific conclusions regarding MDPV at this point in time.

A comprehensive scheduling assessment is now underway with a target timeline of August 2012.

During the regulatory process, Health Canada (HC) will communicate via its website and social media that the use of this substance is dangerous.

s.21(1)(a)
s.21(1)(b)

Fw: ASAP question on Bath Salts
Andria Sherstone to: Johanne Beaulieu

2012-05-31 01:30 PM

Are you fine with my response to Ian below:

OCS has determined that, in light of the extensive references to cocaine and amphetamine-like effects, the statements from health officials and the apparent dangers associated with MDPV,

Mephedrone and methylone are currently proposed to be rescheduled from Schedule III to Schedule I under C-10.

Andria Sherstone
DGO Advisor / Conseillère
Controlled Substances and Tobacco Directorate / Direction des substances contrôlées et de la lutte au tabagisme
Healthy Environments and Consumer Safety Branch / Direction générale de la santé environnementale et de la sécurité des consommateurs
Health Canada / Santé Canada
Tel: (613) 948-8951

----- Forwarded by Andria Sherstone/HC-SC/GC/CA on 2012-05-31 01:30 PM -----

From: Jocelyn Kula/HC-SC/GC/CA
To: Andria Sherstone/HC-SC/GC/CA@HWC
Cc: CSTD-OCS-DO, Johanne Beaulieu/HC-SC/GC/CA@HWC, Tara Phillips/HC-SC/GC/CA@HWC
Date: 2012-05-31 01:21 PM
Subject: Re: Fw: ASAP question on Bath Salts

Please note that the rescheduling of substances proposed in Bill C-10 is not yet in force.

Johanne, Tara and I discussed the possibilities for scheduling this morning and are agreed

Proceeding in this way will also mean that MDPV will be in the same Schedule as mephedrone and methylone (which are both analogs of amphetamines) once the rescheduling of amphetamines from Schedule III to Schedule I is in force.

Happy to discuss
Jocelyn

Jocelyn Kula
Manager, Regulatory Policy Division/ Gestionnaire, Division de la politique réglementaire
Office of Controlled Substances/ Bureau des substances contrôlées
Healthy Environments and Consumer Safety Branch/ Direction générale de la santé environnementale et de la sécurité des consommateurs

Health Canada/ Santé Canada
Tel: (613) 946-0125 Fax: (613) 946-4224

Andria Sherstone Please see another urgent MO request below. ... 2012-05-31 01:01:23 PM

From: Andria Sherstone/HC-SC/GC/CA
To: Johanne Beaulieu/HC-SC/GC/CA@HWC
Cc: Jocelyn Kula/HC-SC/GC/CA@HWC, Tara Phillips/HC-SC/GC/CA@HWC, CSTD-OCS-DO
Date: 2012-05-31 01:01 PM
Subject: Fw: ASAP question on Bath Salts

Please see another urgent MO request below.

ASAP again please.

Andria Sherstone
DGO Advisor / Conseillère
Controlled Substances and Tobacco Directorate / Direction des substances contrôlées et de la lutte au tabagisme
Healthy Environments and Consumer Safety Branch / Direction générale de la santé environnementale et de la sécurité des consommateurs
Health Canada / Santé Canada
Tel: (613) 948-8951

----- Forwarded by Andria Sherstone/HC-SC/GC/CA on 2012-05-31 12:59 PM -----

From: Ian Hobler/HC-SC/GC/CA
To: "Andria Sherstone" <andria.sherstone@hc-sc.gc.ca>
Date: 2012-05-31 12:58 PM
Subject: Fw: ASAP question on Bath Salts

George Kitchen

----- Original Message -----

From: George Kitchen
Sent: 2012-05-31 12:56 PM EDT
To: Steven Schwendt; Ian Hobler; Linsey Hollett
Subject: ASAP question on Bath Salts

Can we confirm info requested below

Leah Canning

----- Original Message -----

From: Leah Canning
Sent: 2012-05-31 12:52 PM EDT
To: George Kitchen; Graham Howell; Ted Laking; Steve Cuthouse
Cc: Sandra Buckler
Subject: Re: Bath Salts

George,

Bill C-10 moved some amphetamines from schedule III to schedule I, which has higher penalties. Can you please confirm asap that the two substances remained on schedule III and that is appropriate to also schedule MDPV to schedule III rather than schedule I?

Thanks,

Leah

George Kitchen Hello Ted, In preparation for our 6:00am call, I... 2012-05-29 06:20 PM EDT

s.21(1)(a)

s.21(1)(b)

Re: Fw: Revised NOI and Critical Path for MDPV 

Andria Sherstone to: Johanne Beaulieu

Cc: Tara Phillips, Jocelyn Kula

2012-05-31 01:53 PM

Thanks! Could I also have the french NOI?

Andria Sherstone
DGO Advisor / Conseillère
Controlled Substances and Tobacco Directorate / Direction des substances contrôlées et de la lutte au tabagisme
Healthy Environments and Consumer Safety Branch / Direction générale de la santé environnementale et de la sécurité des consommateurs
Health Canada / Santé Canada
Tel: (613) 948-8951

Johanne Beaulieu The critical path includes two options: one with... 2012-05-31 01:39:18 PM

From: Johanne Beaulieu/HC-SC/GC/CA
To: Andria Sherstone/HC-SC/GC/CA@HWC
Date: 2012-05-31 01:39 PM
Subject: Fw: Revised NOI and Critical Path for MDPV

Let me know if you need anything else.

Johanne
Johanne Beaulieu
Director | Directrice
Office of Controlled Substances | Bureau des substances contrôlées
Controlled Substances and Tobacco Directorate | Direction des substances contrôlées et de la lutte au tabagisme
Healthy Environments and Consumer Safety Branch | Direction générale de la santé environnementale et de la sécurité des consommateurs
123 Slater Street, Room D-387 | 123 rue Slater, Pièce D-387
Ottawa, Ontario K1A 0K9
(T) 613 952-2177
(F) 613 946-4224
----- Forwarded by Johanne Beaulieu/HC-SC/GC/CA on 2012-05-31 01:38 PM -----

From: Jocelyn Kula/HC-SC/GC/CA
To: Johanne Beaulieu/HC-SC/GC/CA@HWC
Cc: Tara Phillips/HC-SC/GC/CA@HWC, Nathan Isotalo/HC-SC/GC/CA@HWC
Date: 2012-05-31 01:33 PM
Subject: Revised NOI and Critical Path for MDPV

For your review and approval. The NOI has been approved by  and ORS.

[attachment "NOI MDPV 2012-05-31 1pm.doc" deleted by Andria Sherstone/HC-SC/GC/CA]

[attachment "Critical Path for Scheduling of MDPV May 31 2012.docx" deleted by Andria Sherstone/HC-SC/GC/CA]

Jocelyn

Jocelyn Kula
Manager, Regulatory Policy Division/ Gestionnaire, Division de la politique réglementaire
Office of Controlled Substances/ Bureau des substances contrôlées
Healthy Environments and Consumer Safety Branch/ Direction générale de la santé environnementale et
de la sécurité des consommateurs
Health Canada/ Santé Canada
Tel: (613) 946-0125 Fax: (613) 946-4224

s.21(1)(a)
s.21(1)(b)



Fw: NOI - MDPV

Andria Sherstone to: Johanne Beaulieu
Cc: Jocelyn Kula, Tara Phillips

2012-05-31 03:38 PM

FYI - sent to ADMO. Note that one minor change was made to paragraph 3 as per discussion with Tara.

Also, Cathy requested that the critical path be updated to show
Ian also removed

Thanks!

-A

Andria Sherstone
DGO Advisor / Conseillère
Controlled Substances and Tobacco Directorate / Direction des substances contrôlées et de la lutte au
tabagisme
Healthy Environments and Consumer Safety Branch / Direction générale de la santé environnementale et
de la sécurité des consommateurs
Health Canada / Santé Canada
Tel: (613) 948-8951

----- Forwarded by Andria Sherstone/HC-SC/GC/CA on 2012-05-31 03:14 PM -----

From: Andria Sherstone/HC-SC/GC/CA
To: Ian Hobler/HC-SC/GC/CA@HWC
Date: 2012-05-31 02:46 PM
Subject: NOI - MDPV

Hi Ian,

Attached below, please find the NOI for MDPV. The French version of the NOI will be complete by COB
today.

NOI MDPV May 31 2012 - Eng.doc

Also, below please find a critical path developed by OCS for getting MDPV scheduled. You'll note there
are two options for scheduling.

Critical Path for Scheduling of MDPV May 31 2012.docx

Happy to discuss.
-A

Andria Sherstone
DGO Advisor / Conseillère
Controlled Substances and Tobacco Directorate / Direction des substances contrôlées et de la lutte au
tabagisme

Healthy Environments and Consumer Safety Branch / Direction générale de la santé environnementale et
de la sécurité des consommateurs
Health Canada / Santé Canada
Tel: (613) 948-8951

DEPARTMENT OF HEALTH

CONTROLLED DRUGS AND SUBSTANCES ACT

Notice to interested parties – Proposed amendment to Schedule I to the Controlled Drugs and Substances Act

This notice provides interested stakeholders with the opportunity to provide comments on Health Canada's intent to add methylenedioxypyrovalerone (MDPV), namely 3,4-methylenedioxypyrovalerone and its salts, derivatives, isomers and analogues and salts of derivatives, isomers and analogues to Schedule I to the *Controlled Drugs and Substances Act* (CDSA).

MDPV is a synthetic drug that is used for its stimulant-like psychoactive effects. Stimulants in general may significantly increase blood pressure, heart rate and pulse. Adverse physical effects associated with the use of stimulants can include irregular or abnormal heartbeat, heart attack or cardiovascular collapse. There have been reports that MDPV use has also been associated with severe panic attacks and anxiety, as well as hallucinations and psychosis.

Although MDPV is not listed in any of the United Nations Drug Control Convention Schedules, a number of countries have already elected to regulate it as a controlled substance including the United States, Australia, Denmark, Sweden and the United Kingdom.

Health Canada is proposing to include MDPV in Schedule I to the CDSA in order to prohibit the following activities with this substance: possession, trafficking, possession for the purpose of trafficking, importation, exportation, possession for the purpose of exportation, and production. The scheduling of MDPV will also ensure law enforcement can take action under the CDSA against all suspected illegal activities involving MDPV.

This proposed action is in response to concerns expressed by health officials and recent increases in law enforcement and border seizures of products labelled as "bath salts". Such products are not genuine bath salt products intended for softening and/or cleansing the skin, but contain one or more substances with stimulant properties including mephedrone and methylone (which are already included in Schedule III to the CDSA as analogues of amphetamine), and MDPV. While the extent of their use in Canada is unknown, "bath salt" products are available for purchase on the Internet and may be found in alternative lifestyle stores. These products may also be labelled as "plant food" and/or "not for human consumption". Examples of product names include "MITSEEZ", "MOJO Novelty Bath Salts", "Ivory Snow", "Purple Wave", and "Vanilla Sky".

The publication of this notice begins a 30-day comment period. If you are interested in this process or have comments on this notice, please contact Mr. Nathan Isotalo, Regulatory Policy Division, Office of Controlled Substances, Address Locator: 3503D, 123 Slater St., Ottawa, Ontario, Canada, K1A 0K9, by fax at (613) 946-4224 or by email

at OCS_regulatorypolicy-BSC_politiquereglementaire@hc-sc.gc.ca. In particular, parties who believe they are conducting legitimate activities involving MDPV are encouraged to respond to inform Health Canada's decision with respect to regulation of MDPV under the CDSA.

Cathy Sabiston
Director General
Controlled Substance and Tobacco Directorate

Page(s) 000080 to\à 000080

**Is(Are) exempted pursuant to section(s)
est(sont) exemptée(s) en vertu de(s)(l')article(s)**

21(1)(a), 21(1)(b)

**of the Access to Information Act
de la Loi sur l'accès à l'information**



Fw: MDPV (Bath Salts) - NOI
Andria Sherstone to: Johanne Beaulieu

2012-06-01 12:12 PM

Andria Sherstone
DGO Advisor / Conseillère
Controlled Substances and Tobacco Directorate / Direction des substances contrôlées et de la lutte au tabagisme
Healthy Environments and Consumer Safety Branch / Direction générale de la santé environnementale et de la sécurité des consommateurs
Health Canada / Santé Canada
Tel: (613) 948-8951

----- Forwarded by Andria Sherstone/HC-SC/GC/CA on 2012-06-01 12:12 PM -----

From: Ian Hobler/HC-SC/GC/CA
To: Andria Sherstone/HC-SC/GC/CA@HWC
Date: 2012-06-01 12:08 PM
Subject: Fw: MDPV (Bath Salts) - NOI

----- Forwarded by Ian Hobler/HC-SC/GC/CA on 2012-06-01 12:08 PM -----

From: Steven Schwendt/HC-SC/GC/CA
To: Ian Hobler/HC-SC/GC/CA@HWC
Date: 2012-05-31 05:02 PM
Subject: Re: MDPV (Bath Salts) - NOI

Thx!

Ian Hobler Looks good. See my one minor change in bold... 2012-05-31 04:56 PM EDT

From: Ian Hobler
To: Steven Schwendt
Cc:
Date: 2012-05-31 04:56 PM EDT
Subject: Fw: MDPV (Bath Salts) - NOI

Looks good. See my one minor change in **bold underline**.

Thanks for your help.

----- Forwarded by Ian Hobler/HC-SC/GC/CA on 2012-05-31 04:54 PM -----

From: Steven Schwendt/HC-SC/GC/CA
To: Ian Hobler/HC-SC/GC/CA@HWC
Date: 2012-05-31 04:53 PM
Subject: MDPV (Bath Salts) - NOI

thoughts?

s.21(1)(a)
s.21(1)(b)

Hi,

Attached is a *Notice to Interested Parties* (NOI) that outlines a proposal to add MDPV (the currently unregulated ingredient in "bath salts") to Schedule I of the *Controlled Drugs and Substances Act*.

The earliest date the NOI could be published in the *Canada Gazette*, Part I is on Saturday June 9, 2012. In order to publish on this date, HECSB would need to submit it to PCO no later than noon tomorrow, June 1, 2012. The *NOI* has the required approval at the DG level and HECS will have the required package ready in time for submission to PCO to meet this deadline.

[REDACTED]

Please let me know if you have questions on the NOI or concerns with proceeding as outlined above.

Thanks.
Steve

[attachment "NOI MDPV May 31 2012 - Eng.doc" deleted by Ian Hobler/HC-SC/GC/CA]



Fw: MDPV Notice in Canada Gazette, Part I
Andria Sherstone to: Cathy A Sabiston

2012-06-11 01:10 PM

FYI

Andria Sherstone
DGO Advisor / Conseillère
Controlled Substances and Tobacco Directorate / Direction des substances contrôlées et de la lutte au tabagisme
Healthy Environments and Consumer Safety Branch / Direction générale de la santé environnementale et de la sécurité des consommateurs
Health Canada / Santé Canada
Tel: (613) 948-8951

----- Forwarded by Andria Sherstone/HC-SC/GC/CA on 2012-06-11 01:10 PM -----

From: Tara Phillips/HC-SC/GC/CA
To: Jocelyn Kula/HC-SC/GC/CA@HWC, Johanne Beaulieu/HC-SC/GC/CA@HWC, Andria Sherstone/HC-SC/GC/CA@HWC
Cc: Nathan Isotalo/HC-SC/GC/CA@HWC
Date: 2012-06-11 01:10 PM
Subject: MDPV Notice in Canada Gazette, Part I

Hi All,

The MDPV Notice was published this past Saturday in *Canada Gazette*, Part I and can be viewed here:

<http://www.gazette.gc.ca/rp-pr/p1/2012/2012-06-09/html/notice-avis-eng.html#d106>

Tara

Tara Phillips
Regulatory Policy Division / Division des politiques réglementaires
Office of Controlled Substances /
Bureau des substances contrôlées
Health Canada / Santé Canada
Tel/Tél : 613-946-6521
Fax/Télécopieur : 613-946-4224
Email / Courriel : tara.phillips@hc-sc.gc.ca